[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 135
1. Bannykh SI, Stolt CC, Kim J, Perry A, Wegner M: Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas. J Neurooncol; 2006 Jan;76(2):115-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oligodendroglial-specific transcriptional factor SOX10 is ubiquitously expressed in human gliomas.
  • Whereas prototypical examples of the tumors have distinct pathogenetic and prognostic differences, the majority of the gliomas falls in the intermediate category and their distinction is problematic.
  • The transcriptional factor SOX10 is one of the key determinants of oligodendroglial differentiation.
  • High levels of expression were also found in pilocytic astrocytoma, consistent with recent studies suggesting that pilocytic astrocytomas have greater overlap with oligodendroglial than astrocytic tumors.
  • [MeSH-major] Brain Neoplasms / metabolism. DNA-Binding Proteins / biosynthesis. Glioma / metabolism. High Mobility Group Proteins / biosynthesis. Oligodendroglia / metabolism. Transcription Factors / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Astrocytes / metabolism. Astrocytoma / metabolism. Basic Helix-Loop-Helix Transcription Factors / metabolism. Biomarkers, Tumor / metabolism. Blotting, Western. Child. Child, Preschool. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Nerve Tissue Proteins / metabolism. SOXE Transcription Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 1998 Feb;18(2):171-3 [9462749.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Oct;35(2):170-5 [12203781.001]
  • [Cites] Mech Dev. 2000 Dec;99(1-2):143-8 [11091082.001]
  • [Cites] Neuropathol Appl Neurobiol. 1987 Sep-Oct;13(5):327-47 [3317103.001]
  • [Cites] Curr Biol. 2002 Jul 9;12(13):1157-63 [12121626.001]
  • [Cites] Neuron. 2000 Feb;25(2):317-29 [10719888.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71 [11556543.001]
  • [Cites] Glia. 2002 Sep;39(3):193-206 [12203386.001]
  • [Cites] Am J Pathol. 1999 Oct;155(4):1261-9 [10514408.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Sep;29(1):16-25 [10918389.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):665-7 [9024702.001]
  • [Cites] Hum Mol Genet. 2001 Nov 15;10(24):2783-95 [11734543.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Oct;62(10):1052-9 [14575240.001]
  • [Cites] Am J Pathol. 1994 Nov;145(5):1175-90 [7977648.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 May;63(5):499-509 [15198128.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):152-8 [11465395.001]
  • [Cites] Brain Pathol. 2004 Jan;14(1):34-42 [14997935.001]
  • [Cites] APMIS. 1989 Jun;97(6):547-55 [2736107.001]
  • [Cites] Glycoconj J. 1996 Jun;13(3):433-43 [8781974.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Feb;63(2):170-9 [14989603.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):161-81 [15674476.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Genes Dev. 2003 Jul 1;17(13):1677-89 [12842915.001]
  • [Cites] J Neurosci. 2005 Feb 9;25(6):1354-65 [15703389.001]
  • [Cites] Nat Genet. 1998 Jan;18(1):60-4 [9425902.001]
  • [Cites] Acta Neuropathol. 2004 Mar;107(3):277-82 [14730454.001]
  • [Cites] Cancer. 2003 May 1;97(9):2254-61 [12712480.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1041-50 [10515227.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):207-10 [7622310.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Cancer. 2003 Mar 1;97(5):1276-84 [12599236.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Microsc Res Tech. 2001 Mar 15;52(6):746-52 [11276127.001]
  • [Cites] Science. 2004 Dec 17;306(5704):2111-5 [15604411.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):361-9 [15004559.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] Neuropathol Appl Neurobiol. 1996 Aug;22(4):302-10 [8875464.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):983-90 [10839259.001]
  • [Cites] Genes Dev. 2002 Jan 15;16(2):165-70 [11799060.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5161-5 [9560246.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] Oncogene. 1996 Dec 5;13(11):2483-5 [8957092.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10851-6 [11526205.001]
  • [Cites] Cell. 2002 Apr 5;109(1):75-86 [11955448.001]
  • [Cites] Int J Cancer. 1994 Apr 15;57(2):172-5 [8157354.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):344-50 [12924709.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):121-30 [15193024.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):476-87 [12600941.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Aug;57(8):791-802 [9720494.001]
  • [Cites] Front Biosci. 2003 Jan 01;8:a1-9 [12456321.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1717-25 [15111318.001]
  • [Cites] Mod Pathol. 2001 Sep;14(9):842-53 [11557779.001]
  • [Cites] J Neurooncol. 2004 May;67(3):265-71 [15164981.001]
  • [Cites] Mol Cell Biol. 2000 May;20(9):3198-209 [10757804.001]
  • [Cites] Adv Anat Pathol. 2001 Jul;8(4):183-99 [11444508.001]
  • [Cites] Cell. 2002 Apr 5;109(1):61-73 [11955447.001]
  • [Cites] Acta Neuropathol. 1986;72(1):15-22 [2435103.001]
  • [Cites] Cancer Res. 1992 Aug 1;52(15):4277-9 [1353411.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 31;96(18):10361-6 [10468613.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Feb;31(1):62-9 [15634232.001]
  • [Cites] Lancet. 2001 Jul 28;358(9278):298-300 [11498220.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Nov;62(11):1118-28 [14656070.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):267-73 [12675321.001]
  • [Cites] J Neurosci. 1998 Jan 1;18(1):237-50 [9412504.001]
  • [Cites] Genes Dev. 2001 Jan 1;15(1):66-78 [11156606.001]
  • [Cites] Oncogene. 2002 Jun 6;21(25):3961-8 [12037678.001]
  • (PMID = 16205963.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / High Mobility Group Proteins; 0 / Nerve Tissue Proteins; 0 / OLIG1 protein, human; 0 / OLIG2 protein, human; 0 / SOX10 protein, human; 0 / SOXE Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


2. Lavon I, Zrihan D, Zelikovitch B, Fellig Y, Fuchs D, Soffer D, Siegal T: Longitudinal assessment of genetic and epigenetic markers in oligodendrogliomas. Clin Cancer Res; 2007 Mar 1;13(5):1429-37
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Because little is known about the evolution of genetic and epigenetic changes that occur during tumor progression in oligodendrogliomas, we evaluated these changes in paired early and progressive oligodendrogliomas.
  • RESULTS: In early tumors, 60.8% were of low grade compared with only 17% low-grade tumors at recurrence.
  • Of 17 early tumors described as pure oligodendrogliomas, 76.5% remained in this lineage, regardless of their grade, whereas others changed to astrocytic tumors.
  • Oligoastrocytic tumors had a significantly higher tendency to transform to astrocytic tumors.
  • All pure oligodendrogliomas with 1p/19q codeletions remained phenotypically unchanged, unlike mixed tumors with codeletions, of which 83% changed their cell lineage.
  • Of tumors with early 1p deletion, 80% remained oligodendroglial at progression, whereas 75% of tumors with an intact 1p changed to astrocytic phenotype.
  • 10q loss was uncommon in both early and progressive tumors.
  • The proportional gain in methylation at progression was 31% for tumors with early 1p deletion, unlike tumors with an intact 1p, which had an 87.5% gain of methylation at progression.
  • CONCLUSIONS: Pure oligodendrogliomas with 1p/19q deletion tend to retain their cell phenotype and genetic profile unlike tumors with no deletions or mixed histology.
  • MGMT promoter methylation is more pronounced at tumor progression, particularly in tumors with an intact 1p.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Methylation. Epigenesis, Genetic. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Female. Humans. Immunohistochemistry. Male. Microsatellite Repeats. Middle Aged. Phenotype. Polymerase Chain Reaction. Promoter Regions, Genetic. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17332285.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


3. Volavsek M, Lamovec J, Popović M: Extraneural metastases of anaplastic oligodendroglial tumors. Pathol Res Pract; 2009;205(7):502-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extraneural metastases of anaplastic oligodendroglial tumors.
  • Fine needle aspiration biopsy (FNAB) of the cervical lymph node prior to neck dissection suggested a possible metastatic primitive neuroepithelial tumor.
  • It is important to bear this in mind, particularly in cases when the history of primary brain tumor is unavailable.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Femoral Neoplasms / secondary. Neoplasm Recurrence, Local. Oligodendroglia / pathology. Oligodendroglioma / secondary. Sacrum / pathology. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Adjuvant. Cranial Irradiation. Craniotomy. Fatal Outcome. Female. Humans. Lymphatic Metastasis. Middle Aged. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19410385.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


Advertisement
4. Scheie D, Andresen PA, Cvancarova M, Bø AS, Helseth E, Skullerud K, Beiske K: Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors. Am J Surg Pathol; 2006 Jul;30(7):828-37
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorescence in situ hybridization (FISH) on touch preparations: a reliable method for detecting loss of heterozygosity at 1p and 19q in oligodendroglial tumors.
  • Combined loss of heterozygosity (LOH) on 1p and 19q is reported in 50% to 90% of oligodendroglial tumors and has emerged as a strong and favorable prognostic factor.
  • The aim of this study was to evaluate the reliability of FISH to predict LOH at 1p and 19q when performed on touch preparations from 40 oligodendroglial tumors, even if the majority of the nuclei showed chromosomal imbalance.
  • Under these conditions, even a dominant population of nuclei showing FISH-imbalance represented an LOH status in the tumor cells.
  • [MeSH-minor] Adult. Aged. Cell Count. DNA, Neoplasm / analysis. Humans. Middle Aged. Polymerase Chain Reaction. Reproducibility of Results

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16819324.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


5. Roldán G, Scott J, George D, Parney I, Easaw J, Cairncross G, Forsyth P, Yan E: Leptomeningeal disease from oligodendroglioma: clinical and molecular analysis. Can J Neurol Sci; 2008 May;35(2):204-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with both oligodendroglial tumors and LMD were identified.
  • Median age at tumor diagnosis was 41 years (range, 28-50).
  • None had radiographic or pathological evidence of leptomeningeal or subependymal tumor at initial diagnosis.
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Longitudinal Studies. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574935.001).
  • [ISSN] 0317-1671
  • [Journal-full-title] The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
  • [ISO-abbreviation] Can J Neurol Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


6. Taillibert S, Vincent LA, Granger B, Marie Y, Carpentier C, Guillevin R, Bellanger A, Mokhtari K, Rousseau A, Psimaras D, Dehais C, Sierra del Rio M, Meng Y, Laigle-Donadey F, Hoang-Xuan K, Sanson M, Delattre JY: Bevacizumab and irinotecan for recurrent oligodendroglial tumors. Neurology; 2009 May 5;72(18):1601-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab and irinotecan for recurrent oligodendroglial tumors.
  • BACKGROUND: Treatment with a regimen of bevacizumab-irinotecan has been shown to be effective in recurrent grade 3 and 4 gliomas, but the effect of this regimen against recurrent oligodendroglial tumors has not been specifically studied.
  • METHODS: The bevacizumab-irinotecan regimen was retrospectively evaluated in a consecutive series of 25 patients with recurrent oligodendroglial tumors.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Brain Neoplasms / drug therapy. Camptothecin / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Angiogenesis Inhibitors / administration & dosage. Angiogenesis Inhibitors / adverse effects. Antibodies, Monoclonal, Humanized. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / adverse effects. Bevacizumab. Cerebral Hemorrhage / epidemiology. DNA Mutational Analysis. Female. Genetic Predisposition to Disease / genetics. Genetic Testing. Humans. Male. Middle Aged. Patient Compliance. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurology. 2010 Jan 12;74(2):181 [20065257.001]
  • (PMID = 19414728.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents, Phytogenic; 2S9ZZM9Q9V / Bevacizumab; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. French PJ, Swagemakers SM, Nagel JH, Kouwenhoven MC, Brouwer E, van der Spek P, Luider TM, Kros JM, van den Bent MJ, Sillevis Smitt PA: Gene expression profiles associated with treatment response in oligodendrogliomas. Cancer Res; 2005 Dec 15;65(24):11335-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oligodendrogliomas are a specific subtype of brain tumor of which the majority responds favorably to chemotherapy.
  • In this study, we made use of expression profiling to identify chemosensitive oligodendroglial tumors.
  • Correlation of expression profiles to the tumors' response to treatment identified 16 differentially expressed probe sets.
  • Because transcripts associated with chemotherapeutic response were identified independent of common chromosomal aberrations, expression profiling may be used as an alternative approach to the tumors' 1p status to identify chemosensitive oligodendroglial tumors.
  • The observation that many genes are differentially expressed between long and short survivors indicates that the genetic background of the tumor is an important factor in determining the prognosis of the patient.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA, Neoplasm / genetics. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Survival Rate. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16357140.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


8. Fuller CE, Perry A: Molecular diagnostics in central nervous system tumors. Adv Anat Pathol; 2005 Jul;12(4):180-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostics in central nervous system tumors.
  • In this regard, the field is primed by recent advances in basic research, elucidating the molecular mechanisms of tumorigenesis and progression in the most common adult and pediatric brain tumors.
  • Thus far, few have made the transition into routine clinical practice, the most notable example being 1p and 19q testing in oligodendroglial tumors.
  • The goal of this article is to highlight the most common genetic alterations currently implicated in CNS tumors, focusing most on those that are either already in common use in ancillary molecular diagnostics testing or are likely to become so in the near future.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Central Nervous System Neoplasms / genetics. Ependymoma / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Animals. Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Chromosome Aberrations. Humans. In Situ Hybridization, Fluorescence. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / genetics. Meningioma / diagnosis. Meningioma / genetics. Neoplasms, Germ Cell and Embryonal / diagnosis. Neoplasms, Germ Cell and Embryonal / genetics. Polymerase Chain Reaction. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16096380.001).
  • [ISSN] 1072-4109
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 260
  •  go-up   go-down


9. Jeon YK, Park K, Park CK, Paek SH, Jung HW, Park SH: Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization. Neuropathology; 2007 Feb;27(1):10-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1p and 19q status and p53 and p16 expression patterns as prognostic indicators of oligodendroglial tumors: a clinicopathological study using fluorescence in situ hybridization.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Genes, p16 / physiology. Genes, p53 / physiology. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Female. Gene Expression. Gene Expression Profiling. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Prognosis. Survival Analysis. Tissue Array Analysis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17319279.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


10. Emblem KE, Scheie D, Due-Tonnessen P, Nedregaard B, Nome T, Hald JK, Beiske K, Meling TR, Bjornerud A: Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes. AJNR Am J Neuroradiol; 2008 Oct;29(9):1664-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histogram analysis of MR imaging-derived cerebral blood volume maps: combined glioma grading and identification of low-grade oligodendroglial subtypes.
  • BACKGROUND AND PURPOSE: Inclusion of oligodendroglial tumors may confound the utility of MR based glioma grading.
  • Our aim was, first, to assess retrospectively whether a histogram-analysis method of MR perfusion images may both grade gliomas and differentiate between low-grade oligodendroglial tumors with or without loss of heterozygosity (LOH) on 1p/19q and, second, to assess retrospectively whether low-grade oligodendroglial subtypes can be identified in a population of patients with high-grade and low-grade astrocytic and oligodendroglial tumors.
  • RESULTS: Of the 52 patients, 22 had oligodendroglial tumors.
  • The histogram method was able to differentiate high-grade gliomas (HGGs) from low-grade gliomas (LGGs) (Mann-Whitney U test, P < .001) and to identify low-grade oligodendroglial subtypes (P = .009).
  • The sensitivity and specificity in terms of differentiating low-grade oligodendroglial tumors without LOH on 1p/19q from the other tumors was 100% (6/6) and 91% (42/46), respectively.
  • CONCLUSION: With histology as a reference, our results suggest that histogram analysis of MR imaging-derived rCBV maps can differentiate HGGs from LGGs as well as low-grade oligodendroglial subtypes with high interobserver agreement.
  • Also, the method was able to identify low-grade oligodendroglial tumors without LOH on 1p/19q in a population of patients with astrocytic and oligodendroglial tumors.
  • [MeSH-major] Blood Volume / physiology. Brain Neoplasms / blood supply. Glioma / blood supply. Image Processing, Computer-Assisted / methods. Magnetic Resonance Angiography / methods. Oligodendroglioma / blood supply
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18583405.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


11. Ramirez C, Bowman C, Maurage CA, Dubois F, Blond S, Porchet N, Escande F: Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment? Neuro Oncol; 2010 May;12(5):490-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of 1p, 19q, and 10q heterozygosity prospectively predicts prognosis of oligodendroglial tumors--towards individualized tumor treatment?
  • The purpose of this study was to determine whether chromosome 10q loss is a predictor of tumor aggressiveness and poor clinical outcome in patients with oligodendroglial tumors alone or together with loss of heterozygosity (LOH) on chromosomes 1p and 19q.
  • A microsatellite analysis was performed on sections from 130 patients with grade II and grade III oligodendroglial tumors to assess the allelic status of chromosomes 1p, 19q, and 10q, plus detailed clinical and radiological information was taken prospectively.
  • There was a significant association between LOH status and the tumors' response to chemotherapy: 92.3% with 1p19q LOH, 83.3% without allelic losses, 50% with 1p19q10q LOH, and 14.5% with 10q LOH.
  • 10q LOH predicted a survival disadvantage in patients with oligodendroglial tumors irrespective of 1p/19q LOH status.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Disease-Free Survival. Drug Resistance, Neoplasm / genetics. Female. Humans. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Precision Medicine / methods. Prognosis. Young Adult


12. Kapoor GS, Gocke TA, Chawla S, Whitmore RG, Nabavizadeh A, Krejza J, Lopinto J, Plaum J, Maloney-Wilensky E, Poptani H, Melhem ER, Judy KD, O'Rourke DM: Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol; 2009 May;92(3):373-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have recently shown that magnetic resonance perfusion-weighted imaging (MR-PWI) may be useful in predicting the histopathological grade or cytogenetic type of oligodendroglial neoplasms.
  • MR-PWI allows noninvasive determination of relative tumor blood volume (rTBV), which may reflect the degree of neoplastic angiogenesis and metabolism.
  • The present study was aimed to correlate rTBV to the angiogenic markers and EGFR expression in oligodendroglial tumors with 1p/19q LOH or 1p LOH (Group 1) and 1p19q intact alleles or 19q LOH (Group 2), respectively.
  • However, the differences between Group 1 and Group 2 were not significant in grade III tumors.
  • Probe-based real-time RT-PCR analyses showed that 12% of Group 2 high-grade tumors with intact 1p19q exhibited dramatic EGFR overexpression (designated EGFR-high).
  • Group 1 tumors showed significantly higher rTBV than Group 2 tumors, independent of the EGFR-high subtype.
  • Real-time RT-PCR analyses showed increased expression of VEGF, CD31 and CD105 in Group 1 tumors as compared to Group 2 tumors, excluding the EGFR-high subtype.
  • Therefore, the combined use of extensive molecular profiling and advanced MR imaging modalities may improve the accuracy of tumor grading, provide prognostic information, and has the potential to influence treatment decisions.
  • [MeSH-major] Brain Neoplasms / diagnosis. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Neovascularization, Pathologic / diagnosis. Oligodendroglioma / diagnosis. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Female. Humans. In Situ Hybridization, Fluorescence. Loss of Heterozygosity. Magnetic Resonance Angiography. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Invest. 1998;16(4):225-30 [9589031.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] AJNR Am J Neuroradiol. 2004 Feb;25(2):214-21 [14970020.001]
  • [Cites] FASEB J. 2003 Jun;17 (9):984-92 [12773481.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] AJR Am J Roentgenol. 1998 Dec;171(6):1479-86 [9843274.001]
  • [Cites] Clin Cancer Res. 2004 Nov 1;10(21):7182-91 [15534091.001]
  • [Cites] Prostate. 2002 Jun 1;51(4):268-75 [11987155.001]
  • [Cites] Neuropathology. 2008 Feb;28(1):17-23 [18181830.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neurosurg. 2007 Sep;107(3):600-9 [17886561.001]
  • [Cites] Neuro Oncol. 2008 Aug;10(4):540-7 [18544654.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):434-6 [10199331.001]
  • [Cites] J Intern Med. 2004 May;255(5):538-61 [15078497.001]
  • [Cites] Eur J Radiol. 2003 Dec;48(3):244-51 [14652141.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1589-95 [12670909.001]
  • [Cites] AJR Am J Roentgenol. 2002 Mar;178(3):711-6 [11856703.001]
  • [Cites] Stat Med. 1995 Apr 30;14(8):811-9 [7644861.001]
  • [Cites] J Magn Reson Imaging. 2005 Oct;22(4):475-82 [16161080.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):139-46 [10656442.001]
  • [Cites] Lab Invest. 2000 Nov;80(11):1671-80 [11092527.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):738-45 [11857307.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Apr;26(4):777-83 [15814920.001]
  • [Cites] Mol Cancer. 2008 May 20;7:41 [18492260.001]
  • [Cites] J Neurooncol. 2000 Oct-Nov;50(1-2):109-20 [11245271.001]
  • [Cites] AJNR Am J Neuroradiol. 2007 Oct;28(9):1683-9 [17893221.001]
  • [Cites] J Magn Reson Imaging. 2000 Feb;11(2):114-9 [10713942.001]
  • [Cites] Neurosurgery. 2005 May;56(5):919-26; discussion 919-26 [15854239.001]
  • [Cites] Scand J Clin Lab Invest Suppl. 1995;222:43-60 [7569746.001]
  • [Cites] Radiology. 1999 Jun;211(3):791-8 [10352608.001]
  • (PMID = 19357963.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA-90586
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


13. Weller M, Berger H, Hartmann C, Schramm J, Westphal M, Simon M, Goldbrunner R, Krex D, Steinbach JP, Ostertag CB, Loeffler M, Pietsch T, von Deimling A, German Glioma Network: Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin Cancer Res; 2007 Dec 1;13(23):6933-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?
  • PURPOSE: The combined loss of genetic material on chromosomes 1p and 19q is strongly associated with favorable outcome in patients with WHO grade 3 anaplastic oligodendroglial tumors.
  • The prognostic value of 1p/19q loss in WHO grade 2 oligodendroglial tumors is less well defined.
  • CONCLUSIONS: Combined 1p/19q loss is not a sensitive prognostic biomarker in patients with oligodendroglial tumors who do not receive radiotherapy or chemotherapy.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Biomarkers, Tumor / genetics. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18056167.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


14. Lavon I, Refael M, Zelikovitch B, Shalom E, Siegal T: Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades. Neuro Oncol; 2010 Feb;12(2):173-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum DNA can define tumor-specific genetic and epigenetic markers in gliomas of various grades.
  • We evaluated whether cell-free circulating DNA can be used as a noninvasive approach for detection of genetic/epigenetic alterations in brain tumors during the course of the disease.
  • Paired tumor-serum samples from 70 patients with either high-grade astrocytomas (n = 41) or oligodendrogliomas of various grades were analyzed.
  • DNA was extracted from whole blood, serum, and paraffin-embedded tumor sections.
  • LOH and/or methylation that could identify DNA as tumor-specific was found in 80.5% of astrocytic tumors and in all oligodendrogliomas.
  • Statistically significant tumor-serum concordance was found for MGMT methylation in both astrocytic tumors (83%; P < .001) and oligodendroglial tumors (72%; P < .003) and for LOH of 10q (79%; P < .002) and 1p (62%; P < .03) in oligodendrogliomas.
  • We conclude that serum DNA in glial tumors is informative for both LOH and aberrant gene promoter methylation analysis during the course of the disease.
  • The sensitivity is moderate and specificity is high for both low- and high-grade tumors.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. DNA / blood. Glioma / genetics
  • [MeSH-minor] Adult. Aged. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Epigenesis, Genetic. Female. Humans. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. PTEN Phosphohydrolase / genetics. Polymerase Chain Reaction. Sensitivity and Specificity. Tumor Suppressor Proteins / genetics. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2000 Nov 9;343(19):1350-4 [11070098.001]
  • [Cites] Brain Pathol. 2009 Apr;19(2):279-92 [18616639.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1659-65 [11245480.001]
  • [Cites] Nucleic Acids Res. 2001 Jul 1;29(13):E65-5 [11433041.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):371-5 [11809682.001]
  • [Cites] Clin Cancer Res. 2003 Apr;9(4):1461-8 [12684420.001]
  • [Cites] Clin Chem. 2003 Jun;49(6 Pt 1):1028-9 [12766024.001]
  • [Cites] Rocz Akad Med Bialymst. 2003;48:34-41 [14737938.001]
  • [Cites] Pharm Res. 2004 Jul;21(7):1223-8 [15290863.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Pancreas. 1998 Jul;17(1):89-97 [9667526.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):67-70 [9892187.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1219-25 [15709192.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):997-1003 [15758010.001]
  • [Cites] Lung Cancer. 2005 Jul;49(1):1-12 [15949585.001]
  • [Cites] Immunol Lett. 2005 Oct 15;101(1):32-40 [15979158.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 8;102(45):16368-73 [16258065.001]
  • [Cites] Cancer Invest. 2006 Feb;24(1):35-40 [16466990.001]
  • [Cites] Br J Cancer. 2006 May 22;94(10):1492-5 [16641902.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4270-6 [16963729.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:299-307 [17108224.001]
  • [Cites] Ann N Y Acad Sci. 2006 Sep;1075:328-33 [17108228.001]
  • [Cites] Oncogene. 2007 Jan 25;26(4):583-93 [16909125.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):242-51 [17284109.001]
  • [Cites] Br J Cancer. 2007 Mar 12;96(5):681-5 [17311021.001]
  • [Cites] Pathology. 2007 Apr;39(2):197-207 [17454749.001]
  • [Cites] Cancer Res. 2007 May 15;67(10):4545-9 [17510378.001]
  • [Cites] Bioessays. 2007 Jul;29(7):654-67 [17563084.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):548-52 [18385728.001]
  • [Cites] Crit Rev Oncol Hematol. 2008 Jun;66(3):262-72 [18272388.001]
  • [Cites] J Mol Diagn. 2008 Jul;10(4):332-7 [18556773.001]
  • [Cites] BJU Int. 2008 Jul;102(2):253-8 [18336598.001]
  • [Cites] Clin Chem. 2008 Sep;54(9):1528-36 [18653827.001]
  • [Cites] Nat Med. 2008 Sep;14(9):985-90 [18670422.001]
  • [Cites] Clin Chem. 2009 Mar;55(3):559-67 [19131636.001]
  • [Cites] Lung Cancer. 2009 Apr;64(1):92-7 [18804892.001]
  • [Cites] Transfusion. 2001 Feb;41(2):276-82 [11239235.001]
  • (PMID = 20150384.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Proteins; 9007-49-2 / DNA; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC2940579
  •  go-up   go-down


15. Idbaih A, Boisselier B, Marie Y, Sanson M, El Hallani S, Crinière E, Fourtassi M, Paris S, Carpentier C, Rousseau A, Mokhtari K, Combadière C, Laigle-Donadey F, Hoang-Xuan K, Delattre JY: Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res; 2008 Mar 10;1198:16-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors.
  • This SNP has never been specifically investigated in a large series of oligodendroglial tumors.
  • In a comparison with 232 healthy controls, we retrospectively analyzed blood samples of 293 oligodendroglial tumor patients for MDM2 SNP309.
  • In addition, the TP53 R72P polymorphism and chromosome 1p/19q status, a major biomarker in oligodendroglial tumors, were investigated.
  • The frequencies of T/T, T/G, and G/G genotypes in patients and controls did not suggest an increased risk of oligodendroglial tumor formation correlating with MDM2 SNP309.
  • A borderline association was found between MDM2 SNP309 and overall survival (p=0.05), but in multivariate analysis, MDM2 SNP309 did not provide prognostic information complementary to age, tumor phenotype, grade, and 1p/19q status in oligodendroglial tumors.
  • Finally, MDM2 SNP309, alone or in combination with TP53 R72P, was not associated with oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Genetic Predisposition to Disease / genetics. Oligodendroglioma / genetics. Polymorphism, Single Nucleotide / genetics. Proto-Oncogene Proteins c-mdm2 / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Chromosomes, Human, Pair 1 / genetics. DNA Mutational Analysis. Female. Genetic Testing. Genotype. Humans. Male. Middle Aged. Phenotype. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18262501.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


16. Bisdas S, Kirkpatrick M, Giglio P, Welsh C, Spampinato MV, Rumboldt Z: Cerebral blood volume measurements by perfusion-weighted MR imaging in gliomas: ready for prime time in predicting short-term outcome and recurrent disease? AJNR Am J Neuroradiol; 2009 Apr;30(4):681-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND PURPOSE: Current classification and grading of primary brain tumors has significant limitations.
  • MATERIALS AND METHODS: Thirty-four patients with gliomas (WHO grade I-IV, 27 astrocytomas, 7 tumors with oligodendroglial components) underwent contrast-enhanced MR rCBV measurements before treatment.
  • The region of interest and the single pixel with the maximum CBV value within the tumors were normalized relative to the contralateral normal tissue (rCBV(mean) and rCBV(max), respectively).
  • CONCLUSIONS: rCBV values in astrocytomas but not tumors with oligodendroglial components are predictive for recurrence and 1-year survival and may be more accurate than histopathologic grading.
  • [MeSH-major] Astrocytoma / pathology. Blood Volume. Brain Neoplasms / pathology. Cerebrovascular Circulation. Magnetic Resonance Imaging / methods. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Biopsy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Predictive Value of Tests. Prognosis. ROC Curve. Recurrence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179427.001).
  • [ISSN] 1936-959X
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Barresi V, Buttarelli FR, Vitarelli EE, Arcella A, Antonelli M, Giangaspero F: Caveolin-1 expression in diffuse gliomas: correlation with the proliferation index, epidermal growth factor receptor, p53, and 1p/19q status. Hum Pathol; 2009 Dec;40(12):1738-46
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Caveolin-1 (cav-1) has been proposed as an immunohistochemical marker able to distinguish astroglial from oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Caveolin 1 / biosynthesis. Glioma / diagnosis. Receptor, Epidermal Growth Factor / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Cell Proliferation. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Ki-67 Antigen / biosynthesis. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716156.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


18. Wakabayashi T, Natsume A, Hatano H, Fujii M, Shimato S, Ito M, Ohno M, Ito S, Ogura M, Yoshida J: p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery; 2009 Mar;64(3):455-61; discussion 461-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Deoxyribonucleic acid (DNA) methylation of tumor origin can be detected in the serum/plasma of cancer patients.
  • METHODS: The methylation-specific polymerase chain reaction was used to detect p16 methylation in the DNA extracted from 20 astrocytic tumors and 20 oligodendroglial tumors and the corresponding serum samples.
  • In addition, the serum DNA in 7 patients with a brainstem tumor (4 gliomas, 1 schwannoma, 1 cavernous angioma, and 1 ependymoma) was analyzed.
  • Similar methylations were detected in the serum of 9 (75%) of the 12 patients with aberrant methylation in the tumor tissues.
  • No methylated p16 sequences were detected in the peripheral serum of the patients having tumors without these methylation changes or in the 10 healthy controls.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. DNA, Neoplasm / blood. DNA, Neoplasm / genetics. Genes, p16. Glioma / diagnosis. Glioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA Methylation / genetics. Female. Genetic Predisposition to Disease / genetics. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19240607.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm
  •  go-up   go-down


19. Simon M, Neuloh G, von Lehe M, Meyer B, Schramm J: Insular gliomas: the case for surgical management. J Neurosurg; 2009 Apr;110(4):685-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this report the authors summarize their experience with microsurgical resection of insular tumors.
  • RESULTS: A > 90% resection was achieved in 42%, and 70-90% tumor removal was accomplished in 51% of cases.
  • For example, in neurologically intact patients < or = 40 years of age with WHO Grade I-III tumors, good outcomes (Karnofsky Performance Scale Score 80-100) were seen in 91% of cases.
  • The median survival for patients with anaplastic astrocytomas (WHO Grade III) was 5 years, and the 5-year survival rate for those with anaplastic oligodendroglial tumors was 80%.
  • Independent predictors of survival included younger age, favorable histological features (WHO Grade I and oligodendroglial tumors), Yaşargil Type 5A/B tumors with frontal extensions, and more extensive resections.
  • CONCLUSIONS: Insular tumor surgery carries substantial complication rates.
  • In view of the oncological benefits of resective surgery, our data would therefore argue for microsurgery as the primary treatment for most patients with a presumed WHO Grade I-III tumor.
  • [MeSH-major] Brain Neoplasms / surgery. Cerebral Cortex. Glioma / surgery
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Astrocytoma / surgery. Child. Female. Humans. Male. Middle Aged. Postoperative Complications. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099379.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


20. Vogazianou AP, Chan R, Bäcklund LM, Pearson DM, Liu L, Langford CF, Gregory SG, Collins VP, Ichimura K: Distinct patterns of 1p and 19q alterations identify subtypes of human gliomas that have different prognoses. Neuro Oncol; 2010 Jul;12(7):664-78
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We studied the status of chromosomes 1 and 19 in 363 astrocytic and oligodendroglial tumors.
  • Whereas the predominant pattern of copy number abnormality was a concurrent loss of the entire 1p and 19q regions (total 1p/19q loss) among oligodendroglial tumors and partial deletions of 1p and/or 19q in astrocytic tumors, a subset of apparently astrocytic tumors also had total 1p/19q loss.
  • The presence of total 1p/19q loss was associated with longer survival of patients with all types of adult gliomas independent of age and diagnosis (P = .041).
  • The most commonly deleted region on 19q in astrocytic tumors spans 885 kb in 19q13.33-q13.41, which is telomeric to the previously proposed region.
  • Deletion mapping of the centromeric regions of 1p and 19q in the tumors that had total 1p/19q loss, indicating that the breakpoints lie centromeric to NOTCH2 within the pericentromeric regions of 1p and 19q.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Glioma / diagnosis. Glioma / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2002 Jun 6;21(25):3961-8 [12037678.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7787-93 [15520184.001]
  • [Cites] Ann Neurol. 2005 Sep;58(3):483-7 [16130103.001]
  • [Cites] Nat Rev Neurosci. 2006 Feb;7(2):93-102 [16429119.001]
  • [Cites] Nature. 2006 May 18;441(7091):315-21 [16710414.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Jun;65(6):549-61 [16783165.001]
  • [Cites] Cancer Res. 2006 Oct 1;66(19):9428-36 [17018597.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Oct;65(10):988-94 [17021403.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9852-61 [17047046.001]
  • [Cites] Cancer Res. 2006 Dec 1;66(23):11502-13 [17114236.001]
  • [Cites] Cancer Lett. 2007 Feb 8;246(1-2):82-91 [16556484.001]
  • [Cites] Nat Rev Immunol. 2007 Apr;7(4):255-66 [17380156.001]
  • [Cites] Neuro Oncol. 2007 Jul;9(3):314-8 [17435180.001]
  • [Cites] PLoS One. 2007;2(6):e576 [17593975.001]
  • [Cites] J Appl Genet. 2007;48(3):261-8 [17666779.001]
  • [Cites] Brain Pathol. 2007 Oct;17(4):363-70 [17610521.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Res. 2000 Jan 15;60(2):417-24 [10667596.001]
  • [Cites] Clin Cancer Res. 2000 Dec;6(12):4705-12 [11156223.001]
  • [Cites] Endocr Rev. 2001 Apr;22(2):184-204 [11294823.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Cell Signal. 2002 May;14(5):381-95 [11882383.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4100-8 [12124348.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Oct;35(2):97-112 [12203773.001]
  • [Cites] Genes Dev. 2003 Feb 15;17(4):476-87 [12600941.001]
  • [Cites] Clin Cancer Res. 2003 Sep 15;9(11):4151-8 [14519639.001]
  • [Cites] Cancer Res. 2003 Nov 15;63(22):7600-5 [14633674.001]
  • [Cites] Nature. 2004 Apr 1;428(6982):529-35 [15057824.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jun;151(2):182-3 [15172758.001]
  • [Cites] J Neurooncol. 1995;23(3):249-52 [7673988.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):9-15 [9591629.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Jan;67(1):1-15 [18091559.001]
  • [Cites] Clin Cancer Res. 2007 Dec 1;13(23):6933-7 [18056167.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Oct;58(10):1041-50 [10515227.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1778-86 [18076069.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2097-108 [17934521.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2503-10 [18302158.001]
  • [Cites] Cancer Cell. 2008 Apr;13(4):355-64 [18394558.001]
  • [Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18255-60 [19017811.001]
  • [Cites] PLoS One. 2009;4(1):e4107 [19119320.001]
  • [Cites] Cancer Res. 2009 Jan 15;69(2):458-65 [19147558.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3420-5 [19223589.001]
  • [Cites] Cancer Sci. 2009 May;100(5):920-6 [19445024.001]
  • [Cites] Brain Pathol. 1999 Oct;9(4):639-43 [10517502.001]
  • [Cites] J Mol Med (Berl). 2004 Oct;82(10):638-55 [15322700.001]
  • (PMID = 20164239.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6618; United Kingdom / Cancer Research UK / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2940668
  •  go-up   go-down


21. Stockhammer F, Thomale UW, Plotkin M, Hartmann C, Von Deimling A: Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. J Neurosurg; 2007 Apr;106(4):633-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Oligodendroglial tumors harboring combined 1p and 19q loss (1p/19q LOH) are characterized by a favorable prognosis and response to chemotherapy and radiotherapy, but detection of 1p/19q LOH relies on postoperative procedures.
  • The authors investigated the potential of fluorine-18-labeled fluorodeoxyglucose (FDG) uptake in positron emission tomography (PET) to predict 1p/19q LOH preoperatively in tumors whose appearance on initial magnetic resonance images was consistent with that of low-grade glioma.
  • METHODS: The study population comprised 25 patients who had undergone preoperative FDG-PET followed by tumor resection.
  • All tumor specimens were graded according to the World Health Organization (WHO) classification system.
  • Raised glucose utilization within the tumor was seen in the six of eight WHO Grade II gliomas with 1p/19q LOH and in none of the WHO Grade II gliomas without this genetic alteration (p = 0.003).
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / radionuclide imaging. Glioma / genetics. Glioma / radionuclide imaging. Loss of Heterozygosity. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Fluorodeoxyglucose F18. Humans. Male. Microsatellite Repeats / genetics. Middle Aged. Predictive Value of Tests. Radiopharmaceuticals. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17432715.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


22. Tews B, Felsberg J, Hartmann C, Kunitz A, Hahn M, Toedt G, Neben K, Hummerich L, von Deimling A, Reifenberger G, Lichter P: Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. Int J Cancer; 2006 Aug 15;119(4):792-800
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling.
  • Loss of heterozygosity (LOH) on chromosomal arms 1p and 19q is the most common genetic alteration in oligodendroglial tumors and associated with response to radio- and chemotherapy as well as favorable prognosis.
  • Using microsatellite analysis, we previously identified the chromosomal regions 1p36.22-p36.31 and 19q13.3, as candidate tumor suppressor gene regions being commonly deleted in these tumors.
  • To identify genes within these regions that are downregulated in oligodendroglial tumors with LOH 1p/19q, we performed cDNA microarray-based RNA expression profiling of 35 gliomas with known allelic status on 1p and 19q, including 7 oligodendrogliomas and 8 diffuse astrocytomas of World Health Organization (WHO) grade II, as well as 14 anaplastic oligodendrogliomas and 6 anaplastic oligoastrocytomas of WHO grade III.
  • Taken together, our study provides a set of interesting novel candidate genes that may play important roles in the pathogenesis of oligodendroglial tumors.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Oligodendroglioma / genetics. Oligonucleotide Array Sequence Analysis. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child. DNA, Complementary / genetics. Down-Regulation. Female. Humans. Male. Middle Aged. Transcription, Genetic / genetics. Up-Regulation

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16550607.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Complementary; 0 / Tumor Suppressor Proteins
  •  go-up   go-down


23. Walker C, Haylock B, Husband D, Joyce KA, Fildes D, Jenkinson MD, Smith T, Broome J, du Plessis DG, Warnke PC: Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors. Neurology; 2006 Jun 13;66(11):1661-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors.
  • BACKGROUND: The -1p/-19q genotype has been associated with prolonged survival and chemosensitivity in oligodendroglial neoplasms, but the predictive and prognostic significance of genotype in the routine clinic is not established.
  • 1p/19q loss was an independent prognostic factor associated with longer progression-free (PFS) and overall survival (OS) (Cox regression: PFS and OS p < 0.001), with greater impact on PFS than OS in primary tumors, and OS at recurrence.
  • 17p13 loss and p53 mutation were associated with poor prognosis in recurrent tumors and chromosome 10 loss was associated with short PFS and OS in primary tumors.
  • Histologic subtype did not influence outcome in tumors of equivalent genotype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics. Risk Assessment / methods
  • [MeSH-minor] Adult. Aged. Case-Control Studies. DNA Mutational Analysis. Female. Genetic Predisposition to Disease / genetics. Genotype. Humans. Lomustine / administration & dosage. Male. Middle Aged. Procarbazine / administration & dosage. Prognosis. Risk Factors. Survival Rate. Treatment Outcome. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16769937.001).
  • [ISSN] 1526-632X
  • [Journal-full-title] Neurology
  • [ISO-abbreviation] Neurology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  •  go-up   go-down


24. van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M: IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res; 2010 Mar 1;16(5):1597-604
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.
  • [MeSH-major] Brain Neoplasms / genetics. Isocitrate Dehydrogenase / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Disease-Free Survival. Female. Genes, erbB-1. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Lomustine / therapeutic use. Male. Middle Aged. Mutation. Polymerase Chain Reaction. Procarbazine / therapeutic use. Prognosis. Promoter Regions, Genetic. Radiotherapy. Treatment Outcome. Tumor Suppressor Proteins / genetics. Vincristine / therapeutic use. Young Adult


25. Mariani L, Deiana G, Vassella E, Fathi AR, Murtin C, Arnold M, Vajtai I, Weis J, Siegenthaler P, Schobesberger M, Reinert MM: Loss of heterozygosity 1p36 and 19q13 is a prognostic factor for overall survival in patients with diffuse WHO grade 2 gliomas treated without chemotherapy. J Clin Oncol; 2006 Oct 10;24(29):4758-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: We assessed the LOH status of tumors from patients harboring WHO grade 2 gliomas diagnosed between 1991 and 2000.
  • Tumor volume (P < .0001), neurologic deficits at diagnosis (P < .01), involvement of more than one lobe (P < .01), and absence of an oligodendroglial component (P < .05) were also predictors of shorter overall survival.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Glioma / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16966689.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Günther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, Lamszus K: Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene; 2008 May 1;27(20):2897-909
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor cells with stem cell-like properties can be cultured from human glioblastomas by using conditions that select for the expansion of neural stem cells.
  • They showed a multipotent differentiation profile along neuronal, astroglial and oligodendroglial lineages, grew spherically in vitro, expressed CD133 and formed highly invasive tumors in vivo.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Neoplastic Stem Cells / classification. Neoplastic Stem Cells / metabolism. Phenotype
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Cell Culture Techniques. Cell Line, Tumor. Female. Gene Expression Profiling. Humans. Male. Mice. Mice, Nude. Middle Aged. Tumor Cells, Cultured


27. Li KK, Pang JC, Chung NY, Ng YL, Chan NH, Zhou L, Poon WS, Ng HK: EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q. Int J Cancer; 2007 Feb 15;120(4):947-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q.
  • The epithelial membrane protein 3 (EMP3) gene located on chromosome 19q13 has been implicated as a candidate tumor suppressor gene (TSG) in neuroblastomas and gliomas.
  • The aim of this study was to investigate whether EMP3 is involved in oligodendroglial tumors (OTs), which frequently carry combined chromosomes 1p and 19q deletion.
  • Our results showed that 10 (18%) tumors had reduced EMP3 expression level compared to normal brains.
  • Six of these tumors carried chromosome 19q13 deletion but no statistical correlation was found between the 2 parameters.
  • Intriguingly, a similar proportion (11 of 57, 19%) of tumors displayed EMP3 overexpression, with 8 of them having transcript level >10-fold higher than normal brain.
  • All tumors except 3 showed aberrant methylation of EMP3 and no correlation was observed between transcript level and methylation status, suggesting that methylation alone does not mediate transcriptional down-regulation of EMP3 in OTs.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Methylation. Membrane Glycoproteins / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / pathology. Child. CpG Islands. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17187361.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EMP3 protein, human; 0 / Membrane Glycoproteins
  •  go-up   go-down


28. Jha P, Agarwal S, Pathak P, Srivastava A, Suri V, Sharma MC, Chosdol K, Srivastava T, Gupta D, Gupta A, Suri A, Sarkar C: Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India. Cancer Genet Cytogenet; 2010 Apr 15;198(2):126-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterozygosity status of 1p and 19q and its correlation with p53 protein expression and EGFR amplification in patients with astrocytic tumors: novel series from India.
  • There are few reports of loss of heterozygosity (LOH) of 1p and 19q in astrocytic tumors, especially glioblastoma multiforme (GBM).
  • Thus, 1p and 19q LOH can occur in astrocytic tumors, most commonly in secondary GBMs without morphological correlation with an oligodendroglial histology.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Gene Amplification. Genes, erbB-1. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Case-Control Studies. Child. Female. Heterozygote. Humans. India. Loss of Heterozygosity. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20362227.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


29. Heimberger AB, Abou-Ghazal M, Reina-Ortiz C, Yang DS, Sun W, Qiao W, Hiraoka N, Fuller GN: Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas. Clin Cancer Res; 2008 Aug 15;14(16):5166-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: We measured the incidence of Tregs in 135 glial tumors (including all pathologic types) in a glioma microarray using immunohistochemical analysis.
  • Results were categorized according to the total number of Tregs within the tumors.
  • RESULTS: Tregs were not present in normal brain tissue and were very rarely found in low-grade gliomas and oligodendrogliomas.
  • We observed significant differences in the prevalence of Tregs between astrocytic and oligodendroglial tumors, between tumors of different grades, and between different pathologic types of tumors.
  • The presence of Tregs within GBMs did not alter the median survival in patients from whom the tumors were obtained.
  • CONCLUSIONS: Treg infiltration differed significantly in the tumors according to lineage, pathology, and grade.
  • Tregs seemed to have the highest predilection for tumors of the astrocytic lineage and specifically in the high-grade gliomas, such as GBM.
  • [MeSH-major] Biomarkers, Tumor / immunology. Brain Neoplasms / immunology. Forkhead Transcription Factors / metabolism. Glioma / immunology. Lymphocytes, Tumor-Infiltrating / immunology. T-Lymphocytes, Regulatory / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Lineage. Child. Child, Preschool. Female. Flow Cytometry. Humans. Immunohistochemistry. Incidence. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. T-Lymphocyte Subsets / immunology. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18698034.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA120813-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


30. Yao Y, Tang X, Li S, Mao Y, Zhou L: Brain tumor stem cells: view from cell proliferation. Surg Neurol; 2009 Mar;71(3):274-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells: view from cell proliferation.
  • A small population of TSCs, which form neurospheres and possess the capacity for self-renewal, has been recently identified in adult and pediatric brain tumors.
  • They differentiate into phenotypically diverse populations, including neuronal, astrocytic, and oligodendroglial cells in vitro and recapitulate original tumors in vivo.
  • The understanding of brain TSCs has been greatly advanced by the knowledge of cell proliferation, which contributes to initiate and sustain the malignant phenotype.
  • In this article, the authors summarized the evidence of the presence of TSCs in human brain tumors and emphasized the significance of the proliferative status of TSCs.
  • Finally, the preliminary evidence that TSCs in malignant brain tumors have more proliferative capacity than stem/progenitor cells in benign brain tumors was discussed.
  • [MeSH-major] Adult Stem Cells / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249579.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


31. Kilburn L, Okcu MF, Wang T, Cao Y, Renfro-Spelman A, Aldape KD, Gilbert MR, Bondy M: Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. Cancer; 2010 May 1;116(9):2242-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Among the patients with oligodendroglial tumors (n = 94), patients who had the GSTT1 null genotype had a 2.9 times increased risk of death (95% confidence interval [CI], 1.3-6.3) compared with patients who had the GSTT1 non-null genotype.
  • CONCLUSIONS: In patients with anaplastic oligodendroglial tumors, the GSTT1 null genotype may be associated with poor survival, possibly because of modifications in therapy secondary to increased toxicity.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 American Cancer Society.
  • [Cites] Ann Neurol. 1999 Aug;46(2):183-8 [10443883.001]
  • [Cites] Cancer Res. 1999 May 15;59(10):2358-62 [10344744.001]
  • [Cites] Clin Cancer Res. 2005 Mar 15;11(6):2175-9 [15788664.001]
  • [Cites] Blood. 2005 Jun 15;105(12):4752-8 [15713801.001]
  • [Cites] Clin Cancer Res. 2005 Jul 1;11(13):4749-53 [16000570.001]
  • [Cites] J Clin Oncol. 2005 Aug 20;23(24):5552-9 [16110016.001]
  • [Cites] Int J Oncol. 2006 Jan;28(1):231-6 [16328000.001]
  • [Cites] Cancer. 2006 Jan 15;106(2):441-7 [16342067.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):281-6 [16317430.001]
  • [Cites] Clin Cancer Res. 2006 May 15;12(10):3050-6 [16707601.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):708-14 [17228018.001]
  • [Cites] Blood. 2000 Feb 15;95(4):1222-8 [10666194.001]
  • [Cites] Semin Oncol. 2000 Jun;27(3 Suppl 6):11-9 [10866345.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Nov 11;278(1):258-62 [11071881.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):114-23 [11150363.001]
  • [Cites] Pharmacogenetics. 2000 Nov;10(8):715-26 [11186134.001]
  • [Cites] J Clin Oncol. 2001 Mar 1;19(5):1279-87 [11230469.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7130-5 [11585745.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Dec;10(12):1239-48 [11751440.001]
  • [Cites] Leukemia. 2002 Feb;16(2):203-8 [11840286.001]
  • [Cites] Blood. 2002 Jul 1;100(1):67-71 [12070010.001]
  • [Cites] J Natl Cancer Inst. 2002 Jun 19;94(12):936-42 [12072547.001]
  • [Cites] Pharmacogenetics. 2002 Oct;12(7):543-53 [12360105.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):527-33 [12814998.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2618-25 [15102663.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1463-72 [15368334.001]
  • [Cites] Am J Hum Genet. 1981 Jan;33(1):36-43 [7468592.001]
  • [Cites] Semin Oncol. 1986 Mar;13(1):38-45 [3513316.001]
  • [Cites] CRC Crit Rev Biochem. 1988;23(3):283-337 [3069329.001]
  • [Cites] Cancer Res. 1990 Nov 1;50(21):6976-80 [2208164.001]
  • [Cites] Biochem J. 1991 Mar 1;274 ( Pt 2):409-14 [1848757.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4257-61 [8395980.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1995;30(6):445-600 [8770536.001]
  • [Cites] J Biol Chem. 1997 Apr 11;272(15):10004-12 [9092542.001]
  • [Cites] Biochem Biophys Res Commun. 1997 Sep 18;238(2):397-402 [9299520.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2253-61 [9815622.001]
  • [Cites] Arch Biochem Biophys. 1999 Jun 1;366(1):89-94 [10334868.001]
  • [Cites] Science. 1999 Oct 15;286(5439):487-91 [10521338.001]
  • (PMID = 20187096.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA094746-02; United States / NCI NIH HHS / CA / R03 CA094746; United States / NCI NIH HHS / CA / 1R03CA094746; United States / NCI NIH HHS / CA / R03 CA094746-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.1.18 / Glutathione Transferase
  • [Other-IDs] NLM/ NIHMS189687; NLM/ PMC2861043
  •  go-up   go-down


32. Kunitz A, Wolter M, van den Boom J, Felsberg J, Tews B, Hahn M, Benner A, Sabel M, Lichter P, Reifenberger G, von Deimling A, Hartmann C: DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in Human Gliomas. Brain Pathol; 2007 Oct;17(4):363-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Allelic losses on 19q are found in the majority of oligodendroglial tumors and approximately one-third of diffuse astrocytomas.
  • However, the tumor suppressor genes (TSG) on 19q are still elusive.
  • In oligodendroglial tumors, we found that aberrant methylation in the 5'-region of EMP3 was significantly associated with reduced mRNA expression and LOH 19q.
  • Our data corroborate that oligodendroglial and astrocytic gliomas often show EMP3 hypermethylation and aberrant expression.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Methylation. Gene Expression Regulation, Neoplastic / genetics. Glioma / genetics. Membrane Glycoproteins / genetics
  • [MeSH-minor] Adult. Astrocytoma / genetics. Astrocytoma / metabolism. Astrocytoma / physiopathology. Gene Expression Profiling. Gene Silencing / physiology. Genetic Predisposition to Disease / genetics. Humans. Oligodendroglioma / genetics. Oligodendroglioma / metabolism. Oligodendroglioma / physiopathology. Oligonucleotide Array Sequence Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17610521.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / EMP3 protein, human; 0 / Membrane Glycoproteins
  •  go-up   go-down


33. Daumas-Duport C, Koziak M, Miquel C, Nataf F, Jouvet A, Varlet P: [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):247-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Definition of homogeneous tumor groups of oligodendrogliomas or oligo-astrocytomas is a basic condition for an adequate evaluation and comparison of the results of treatments in patients from various institutions.
  • However, increasing discordances are observed in the histological diagnosis of these tumors.
  • PATIENTS AND METHODS: This study included 251 adult patients in whom a SA grade A or B oligodendroglioma or oligo-astrocytoma was newly diagnosed at our institution from 1984 to 2003.
  • The tumors were graded A: no CH and no EH; in B: CH and /or HE++, and A/B: EH + but no CE.
  • RESULTS: 70.1% of the tumors were classified as "pure" oligodendroglioma, 19.5% as "polymorphous oligo-astroastrocytoma" and 10.3% as "gemistocytic oligo-astrocytoma".
  • In grade A, or B tumors, the presence of a polymorphous or a gemistocytic component had no significant influence on survival; however respectively 53% and 65% of these tumours versus 32% of "pure" oligodendrogliomas were grade B at the time of diagnosis.
  • After regrouping of the histological subtypes and of the tumors with HE+ or absent, the series included 153 oligodendrogliomas grade A and 98 grade B.
  • Survival in patients with grade A versus grade B tumors was respectively 142 versus 52 months (p<0.0001).
  • In grade B tumors, necrosis had no significant influence on survival.
  • In tumors with or without CE, patient survival was respectively 148 versus 40 months (p<0.0001).
  • On post contrast MRI done in 235 patients, only 7 tumors (3%) were grade A/B (EH++ but no CH).
  • 1) tumors diagnosed according to the Ste-Anne classification as oligodendroglioma or oligo-astrocytoma be regrouped in a unique category, 2) independent of their histological type and grade according to the WHO, gliomas that do not show CE be regrouped with SA oligodendrogliomas grade A, 3) concerning gliomas that show CE on MRI: oligodendrogliomas or oligo-astrocytomas WHO grade II or III, as well as WHO secondary glioblastomas or glioblastomas with an oligodendroglial component, be regrouped with SA oligodendrogliomas grade B; however tumors that show ring-like CE surrounding large foci of necrosis and finger-like "peritumoral" edema should be excluded or analysed separately.
  • [MeSH-major] Brain / pathology. Brain / radiography. Brain Neoplasms / classification. Glioma / classification. Oligodendroglioma / classification
  • [MeSH-minor] Adult. France. Hospitals. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292168.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


34. McCarthy BJ, Propp JM, Davis FG, Burger PC: Time trends in oligodendroglial and astrocytic tumor incidence. Neuroepidemiology; 2008;30(1):34-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Time trends in oligodendroglial and astrocytic tumor incidence.
  • BACKGROUND: We hypothesized that the incidences of oligodendrogliomas, anaplastic oligodendrogliomas, and mixed gliomas have significantly increased from the early 1990 s forward, while the incidences of anaplastic and grade II astrocytic tumors have significantly decreased.
  • METHODS: Data for the years 1973-2004 from the Surveillance, Epidemiology and End Results (SEER) public-use data and for 1985-2004 from six collaborating registries of the Central Brain Tumor Registry of the US (CBTRUS) were obtained.
  • CONCLUSIONS: This study has demonstrated that increases in oligodendroglial tumor incidence correspond to decreases in astrocytic tumor incidence over the same time period.
  • Minimizing misclassification of glial tumors will be essential for accurately assessing incidence, survival, and mortality rates, as well as for identifying homogeneous subgroups for epidemiologic and treatment studies.
  • [MeSH-major] Astrocytoma / epidemiology. Brain Neoplasms / epidemiology. Glioma / epidemiology. Oligodendroglioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Aged. Child. Child, Preschool. Humans. Incidence. Infant. Infant, Newborn. Middle Aged. Registries / statistics & numerical data. Time. United States / epidemiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18259099.001).
  • [ISSN] 1423-0208
  • [Journal-full-title] Neuroepidemiology
  • [ISO-abbreviation] Neuroepidemiology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


35. Seol HJ, Kim JE, Wang KC, Kim SK, Seo JS, Park SH, Jung HW: The pattern of gene expression and possible relation of steroidogenic genes in oligodendroglial tumors. Int J Oncol; 2009 Jan;34(1):181-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The pattern of gene expression and possible relation of steroidogenic genes in oligodendroglial tumors.
  • StAR is expressed at a very low level in the white matter of the normal human brain, but is highly expressed in several brain neoplasms including oligodendroglioma (OD).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Brain Neoplasms / genetics. Gene Expression Profiling. Oligodendroglioma / genetics. Steroids / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / metabolism. Brain / pathology. Child. Child, Preschool. Fluorescent Antibody Technique. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. Oligonucleotide Array Sequence Analysis. Phosphoproteins / genetics. Phosphoproteins / metabolism. RNA, Neoplasm. Transcription, Genetic. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19082489.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Phosphoproteins; 0 / RNA, Neoplasm; 0 / Steroids; 0 / steroidogenic acute regulatory protein
  •  go-up   go-down


36. Mikami S, Hirose Y, Yoshida K, Kawase T, Ohnishi A, Nagashima K, Mukai M, Okada Y, Ikeda E: Predominant expression of OLIG2 over ID2 in oligodendroglial tumors. Virchows Arch; 2007 May;450(5):575-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.
  • This study aims to examine if the analysis of OLIG2 and ID2 expression in glioma tissues helps the differential diagnosis of chemosensitive oligodendroglial tumors from astrocytic tumors.
  • Expression levels of OLIG2 and ID2 in 11 oligodendroglial and 27 astrocytic tumors were analyzed by reverse transcription-polymerase chain reaction (RT-PCR), real-time quantitative PCR, and immunohistochemistry.
  • The mean expression level of OLIG2 was higher in oligodendroglial tumors than astrocytic tumors, but some astrocytic tumors showed high OLIG2 expression, indicating that OLIG2 cannot be an independent marker of oligodendroglial tumors.
  • No significant difference was observed between ID2 expression in oligodendroglial tumors and astrocytic tumors.
  • It was notable that OLIG2 expression was predominant over ID2 expression in oligodendroglial tumors, while ID2 expression was predominant over OLIG2 expression in astrocytic tumors.
  • These results indicate that the immunohistochemical study on the relative expression level of OLIG2 to ID2 can be a useful screening for oligodendroglial tumors.
  • [MeSH-major] Basic Helix-Loop-Helix Transcription Factors / metabolism. Brain Neoplasms / metabolism. Inhibitor of Differentiation Protein 2 / metabolism. Nerve Tissue Proteins / metabolism. Oligodendroglia / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / metabolism. Astrocytoma / secondary. Astrocytoma / surgery. Biomarkers, Tumor / metabolism. Child. Chromosome Deletion. Chromosomes, Human, Pair 1. Female. Fluorescent Antibody Technique, Direct. Gene Expression. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Nucleic Acid Hybridization. Oligodendroglioma / metabolism. Oligodendroglioma / secondary. Oligodendroglioma / surgery. RNA, Messenger / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 2000 Feb;25(2):317-29 [10719888.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Oct;62(10):1052-9 [14575240.001]
  • [Cites] Glia. 2002 Jun;38(4):329-38 [12007145.001]
  • [Cites] Dev Dyn. 2005 Nov;234(3):489-96 [15880651.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Apr 1;142(1):1-7 [12660025.001]
  • [Cites] Development. 2004 Sep;131(17):4131-42 [15280210.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):802-9 [15637687.001]
  • [Cites] Semin Oncol. 2004 Oct;31(5):618-34 [15497115.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] Cell. 1990 Apr 6;61(1):49-59 [2156629.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10851-6 [11526205.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):344-50 [12924709.001]
  • [Cites] Am J Pathol. 2004 May;164(5):1717-25 [15111318.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):9913-20 [17047053.001]
  • [Cites] Neuron. 2000 Feb;25(2):331-43 [10719889.001]
  • [Cites] Trends Cell Biol. 2003 Aug;13(8):410-8 [12888293.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Feb;31(1):62-9 [15634232.001]
  • [Cites] Curr Treat Options Oncol. 2000 Dec;1(5):459-68 [12057153.001]
  • [Cites] Curr Treat Options Neurol. 2005 Jul;7(4):305-314 [15967093.001]
  • [Cites] Neuron. 2001 Mar;29(3):603-14 [11301021.001]
  • [Cites] J Mol Diagn. 2001 May;3(2):62-7 [11333301.001]
  • (PMID = 17431671.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Biomarkers, Tumor; 0 / ID2 protein, human; 0 / Inhibitor of Differentiation Protein 2; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / RNA, Messenger
  •  go-up   go-down


37. Kaloshi G, Mokhtari K, Carpentier C, Taillibert S, Lejeune J, Marie Y, Delattre JY, Godbout R, Sanson M: FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status. J Neurooncol; 2007 Sep;84(3):245-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • FABP7 expression has been analysed in a series of 123 glioblastomas (68 pure GBM, 55 GBMO, i.e. with oligodendroglial component).
  • Nuclear expression of FABP7 was more specifically related to EGFR amplification and more invasive tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / pathology. Carrier Proteins / biosynthesis. Glioblastoma / pathology. Receptor, Epidermal Growth Factor / metabolism. Tumor Suppressor Proteins / biosynthesis
  • [MeSH-minor] Adult. Aged. Cell Nucleus / metabolism. Cytoplasm / metabolism. Fatty Acid-Binding Protein 7. Female. Gene Amplification. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Invasiveness / pathology. Prognosis. Protein Transport / physiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71 [11556543.001]
  • [Cites] BMC Clin Pathol. 2005 Jul 15;5:6 [16018821.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] BMC Cancer. 2006 Apr 19;6:97 [16623952.001]
  • [Cites] Oncogene. 2007 Apr 26;26(19):2695-706 [17057735.001]
  • [Cites] Cancer. 2006 May 15;106(10 ):2218-23 [16568472.001]
  • [Cites] Oncogene. 1998 Apr 16;16(15):1955-62 [9591779.001]
  • [Cites] Prog Lipid Res. 2004 Jul;43(4):328-49 [15234551.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Apr 19;102(16):5814-9 [15827123.001]
  • [Cites] Genes Dev. 2005 May 1;19(9):1028-33 [15879553.001]
  • [Cites] Neuron. 1994 Apr;12 (4):895-908 [8161459.001]
  • (PMID = 17415524.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / FABP7 protein, human; 0 / Fatty Acid-Binding Protein 7; 0 / Tumor Suppressor Proteins; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


38. Whitmore RG, Krejza J, Kapoor GS, Huse J, Woo JH, Bloom S, Lopinto J, Wolf RL, Judy K, Rosenfeld MR, Biegel JA, Melhem ER, O'Rourke DM: Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg; 2007 Sep;107(3):600-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging.
  • Perfusion weighted magnetic resonance (MR) imaging allows for noninvasive determination of relative tumor blood volume (rTBV) and has been used to predict the grade of astrocytic neoplasms.
  • The aim of this study was to use perfusion weighted MR imaging to predict tumor grade and cytogenetic profile in oligodendroglial neoplasms.
  • METHODS: Thirty patients with oligodendroglial neoplasms who underwent preoperative perfusion MR imaging were retrospectively identified.
  • Tumors were classified by histopathological grade and stratified into two cytogenetic groups: 1p or 1p and 19q loss of heterozygosity (LOH) (Group 1), and 19q LOH only on intact alleles (Group 2).
  • Tumor blood volume was calculated in relation to contralateral white matter.
  • Multivariate logistic regression analysis was used to develop predictive models of cytogenetic profile and tumor grade.
  • CONCLUSIONS: Oligodendroglial classification models derived from advanced imaging will improve the accuracy of tumor grading, provide prognostic information, and have potential to influence treatment decisions.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Loss of Heterozygosity / genetics. Magnetic Resonance Angiography. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Blood Volume. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Tumor Burden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886561.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA-90586
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


39. Barnett JA, Urbauer DL, Murray GI, Fuller GN, Heimberger AB: Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target. Clin Cancer Res; 2007 Jun 15;13(12):3559-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytochrome P450 1B1 expression in glial cell tumors: an immunotherapeutic target.
  • EXPERIMENTAL DESIGN: We studied the frequency and extent of CYP1B1 expression by immunohistochemical analysis in 269 glial tumors (including all major pathologic types) on a tissue microarray.
  • RESULTS: Overall, increased CYP1B1 expression in glial tumors was associated with decreased patient survival time (P < 0.0014 for both percentage and intensity of staining).
  • A significant difference existed in percentage and intensity of staining between astrocytic and oligodendroglial tumors (P = 0.0002 and 0.0003, respectively), between grades of tumors (P < 0.0001 and 0.0079), and between pathologic types of tumors (P < 0.0001 and 0.0339).
  • Paradoxically, within specific tumor pathologies, there was a trend toward increased survival as CYP1B1 expression increased.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Cytochrome P-450 Enzyme System / biosynthesis. Gene Expression. Glioma / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Aryl Hydrocarbon Hydroxylases. Child. Child, Preschool. Cytochrome P-450 CYP1B1. Female. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Male. Middle Aged. Prognosis. Tissue Array Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575219.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / Aryl Hydrocarbon Hydroxylases; EC 1.14.14.1 / CYP1B1 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP1B1
  •  go-up   go-down


40. Ferrer-Luna R, Mata M, Núñez L, Calvar J, Dasí F, Arias E, Piquer J, Cerdá-Nicolás M, Taratuto AL, Sevlever G, Celda B, Martinetto H: Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression. J Neurooncol; 2009 Dec;95(3):343-354
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of heterozygosity at 1p-19q induces a global change in oligodendroglial tumor gene expression.
  • Oligodendroglial tumors presenting loss of heterozygosity (LOH) at 1p and 19q have been shown to be sensitive to chemotherapy, thus making 1p-19q status testing a key aspect in oligodendroglioma diagnosis and prognosis.
  • Twenty-nine tumor samples (19 oligodendrogliomas, 10 oligoastrocytomas) were analyzed in order to obtain a molecular profile identifying those bearing 1p-19q LOH.
  • Tumors with 1p-19q LOH overexpressed genes related to neurogenesis.
  • This molecular signature was validated by analyzing a set of ten tumor samples (three oligodendrogliomas, seven oligoastrocytomas); all ten samples were correctly assigned.
  • Tumors without LOH at 1p-19q exhibit the opposite characteristics, explaining their more aggressive behavior.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Gene Expression Regulation, Neoplastic. Loss of Heterozygosity. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Child, Preschool. Chromosome Deletion. Cluster Analysis. Gene Expression Profiling. Humans. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction


41. Cassoni P, Senetta R, Castellano I, Ortolan E, Bosco M, Magnani I, Ducati A: Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas. Am J Surg Pathol; 2007 May;31(5):760-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Caveolin-1 expression is variably displayed in astroglial-derived tumors and absent in oligodendrogliomas: concrete premises for a new reliable diagnostic marker in gliomas.
  • The distribution of caveolae within the normal brain and in brain tumors is controversial.
  • In the present study, we describe the expression of caveolin-1 (cav-1) in 64 brain tumors of different grade, of either astroglial or oligodendroglial origin.
  • All studied astrocitomas of any grade (from II to IV) were cav-1 positive, displaying staining patterns and intensity specifically associated to the different tumor grades.
  • In contrast to astroglial tumors, the striking totality of grade II oligodendrogliomas and the large majority of grade III were lacking cav-1 expression.
  • In conclusion, among astroglial tumors cav-1 expression varies in distribution, pattern, and intensity specifically according to tumor types and grades.
  • The association between tumor progression and a more structured membranous pattern of cav-1 expression could suggest the hypothesis of a neoplastic shift towards a mesenchymal phenotype, whose behavioral and biologic significance worth further studies.
  • [MeSH-major] Astrocytes / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Caveolin 1 / metabolism. Glioblastoma / metabolism. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Count. Cell Line, Tumor. Cell Separation. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Disease Progression. Flow Cytometry. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460461.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Caveolin 1
  •  go-up   go-down


42. Yakut T, Gutenberg A, Bekar A, Egeli U, Gunawan B, Ercan I, Tolunay S, Doygun M, Schulten HJ: Correlation of chromosomal imbalances by comparative genomic hybridization and expression of EGFR, PTEN, p53, and MIB-1 in diffuse gliomas. Oncol Rep; 2007 May;17(5):1037-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most frequent imbalances in oligodendroglial tumors including the oligoastrocytic case were, in decreasing order of frequency, +7q, -1p, and -4q and in astrocytomas +7q, -10q, +7p, -9p, -10p, +20q, and +20p.
  • In addition, p53 overexpression correlated positively with +7q and negatively with -1p in the oligodendroglial group whereas EGFR overexpression correlated positively with -1p in the oligodendroglial and positively with +7p and -10p in the astrocytic group.
  • Collectively, these results contribute to the increasing clinical relevance of assessing tumor biological markers in gliomas.
  • [MeSH-major] Chromosome Aberrations. Glioma / genetics. PTEN Phosphohydrolase / biosynthesis. Receptor, Epidermal Growth Factor / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis. Ubiquitin-Protein Ligases / biosynthesis
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Infant. Male. Middle Aged. Nucleic Acid Hybridization / methods

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17390041.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  •  go-up   go-down


43. Haapasalo J, Nordfors K, Järvelä S, Bragge H, Rantala I, Parkkila AK, Haapasalo H, Parkkila S: Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy. Neuro Oncol; 2007 Jul;9(3):308-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase II in the endothelium of glial tumors: a potential target for therapy.
  • Carbonic anhydrase isozyme II (CA II) is a cytosolic enzyme that is highly expressed in most organs, including the brain, where it is mainly located in the oligodendrocytes.
  • These results prompted us to investigate endothelial CA II expression in two types of brain cancer: oligodendrogliomas and astrocytomas.
  • A series of 255 astrocytoma and 71 oligodendroglial tumor specimens was immunostained for CA II.
  • CA II showed weak or no expression in low-grade tumors, while grade 3 mixed oligoastrocytoma and glioblastoma multiforme were the most positively stained tumor types.
  • About 17% of patients with CA II-negative tumors (weak or no endothelial signal) were still alive at the end of the follow-up period of five years.
  • The presence of CA II in the tumor endothelium suggests that it may play an important functional role in tumor metabolism.
  • From a clinical perspective, the results also open new avenues for selecting tumor types for dendritic cell therapy trials.
  • [MeSH-major] Brain Neoplasms / enzymology. Carbonic Anhydrase II / biosynthesis. Endothelium, Vascular / enzymology. Glioma / enzymology. Neovascularization, Pathologic / enzymology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Humans. Immunohistochemistry. In Situ Hybridization. Infant. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2000 Feb 29;97(5):2220-4 [10688890.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Aug;32(4):441-50 [16866989.001]
  • [Cites] Dig Dis Sci. 2001 Oct;46(10):2179-86 [11680594.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7992-8 [11691824.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2240-5 [12114426.001]
  • [Cites] Expert Opin Investig Drugs. 2003 Feb;12(2):283-7 [12556221.001]
  • [Cites] Life Sci. 2004 Jul 30;75(11):1277-85 [15234186.001]
  • [Cites] J Enzyme Inhib Med Chem. 2004 Jun;19(3):199-229 [15499993.001]
  • [Cites] J Natl Cancer Inst. 1972 Feb;48(2):347-56 [4347034.001]
  • [Cites] Histochemistry. 1993 Jan;99(1):37-41 [8468192.001]
  • [Cites] Am J Pathol. 1993 May;142(5):1347-51 [7684193.001]
  • [Cites] Histochem J. 1995 Feb;27(2):133-8 [7775197.001]
  • [Cites] Annu Rev Biochem. 1995;64:375-401 [7574487.001]
  • [Cites] Neuropathol Appl Neurobiol. 1999 Apr;25(2):134-42 [10216001.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4160-7 [15930352.001]
  • [Cites] Clin Cancer Res. 2005 Nov 15;11(22):8201-7 [16299253.001]
  • [Cites] Clin Cancer Res. 2006 Jan 15;12(2):473-7 [16428489.001]
  • [Cites] Bioorg Med Chem. 2001 Mar;9(3):703-14 [11310605.001]
  • (PMID = 17435181.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 4.2.1.- / Carbonic Anhydrase II
  • [Other-IDs] NLM/ PMC1907412
  •  go-up   go-down


44. Kanner AA, Staugaitis SM, Castilla EA, Chernova O, Prayson RA, Vogelbaum MA, Stevens G, Peereboom D, Suh J, Lee SY, Tubbs RR, Barnett GH: The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg; 2006 Apr;104(4):542-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Oligodendrogliomas are rare primary brain tumors.
  • They comprise approximately 5 to 33% of all glial tumors but differ from astrocytomas by being associated with a more favorable prognosis, making their correct identification important.
  • Allelic loss of chromosome arms 1p and 19q is found in a substantial subpopulation of tumors with an oligodendroglioma phenotype.
  • METHODS: Oligodendroglial neoplasms were studied using fluorescence in situ hybridization of formalin-fixed, paraffin-embedded tissue specimens; reference and target probe sets were used to map the telomeric regions of 1p and 19q.
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology. Chromosomes, Human, Pair 19. Decision Support Techniques. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Prognosis. Reproducibility of Results. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16619658.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C: Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol; 2010 Aug;120(2):261-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
  • The current WHO classification of brain tumors defines gliomatosis cerebri (GC) as an extensively infiltrating astrocytic glioma involving at least three cerebral lobes.
  • Recent reports showed IDH1 mutations in astrocytic and oligodendroglial tumors WHO grades II and III and in secondary glioblastomas with a frequency of up to 90%, whereas IDH1 mutations occurred in only 5% of primary glioblastomas.
  • We identified IDH1 mutations in 10/24 (42%) cases, which also included a solid tumor portion (type 2 GC), but not in 11 "classical" cases without solid tumor mass (type 1 GC).
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Isocitrate Dehydrogenase / genetics. Mutation / genetics. Neoplasms, Neuroepithelial / genetics. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Arginine / genetics. Astrocytoma / secondary. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. DNA Mutational Analysis. Female. Histidine / genetics. Humans. In Situ Hybridization, Fluorescence / methods. Magnetic Resonance Imaging / methods. Male. Middle Aged. Oligodendroglioma / secondary. Polymorphism, Single Nucleotide / genetics. Tumor Suppressor Protein p53 / genetics. Tumor Suppressor Protein p53 / metabolism


46. Martínez L, Cuesta J, Santos S, Tejero C: [Focal presentation of progressive multifocal leukoencephalopathy: first manifestation of human immunodeficiency virus infection]. Neurologia; 2008 Oct;23(8):532-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Progressive multifocal leukoencephalopathy (PML) is a subacute demyelinating disorder of central nervous system caused by an opportunistic papovavirus infection of oligodendroglial cells, the JC virus.
  • Their antibodies are detectable in 70% of healthy adult subjects.
  • A unique wide hyperintense subcortical right temporoparietal lobe lesion was shown by a cerebral magnetic resonance imaging (MRI), suggesting a differential diagnosis between PLM and low grade glial tumor.
  • DISCUSSION: We report this case to suggest that inva- sive diagnosis methods may be useful to differentiate between PLM and low grade glial tumors and to establish a correct prognosis.
  • [MeSH-minor] Adult. Antiretroviral Therapy, Highly Active. Humans. JC Virus / metabolism. Male

  • Genetic Alliance. consumer health - Progressive multifocal leukoencephalopathy.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392989.001).
  • [ISSN] 0213-4853
  • [Journal-full-title] Neurología (Barcelona, Spain)
  • [ISO-abbreviation] Neurologia
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


47. Derlon JM, Cabal P, Blaizot X, Borha A, Chapon F: [Metabolic imaging for supratentorial oligodendrogliomas]. Neurochirurgie; 2005 Sep;51(3-4 Pt 2):309-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Only a few publications have yet reported its use in oligodendroglial tumors.
  • These findings and partial results obtained in ongoing work, suggest some preliminary conclusions: 11C-MET (L-methyl-methionine) is a more appropriate tracer than 18F-FDG (fluoro-deoxy-glucose), in terms of both specificity and sensitivity, for the assessment of patients with this category of tumor.
  • PET/MET allows differentiation between grade II and grade III oligodendrogliomas; better targeting for stereotactic biopsy; more accurate assessment of the post-operative residual tumor; identification of progression from low-grade to anaplastic grade during the disease course; differentiation between recurrence and a post-radiation processes.
  • [MeSH-major] Brain. Oligodendroglioma / metabolism. Positron-Emission Tomography. Supratentorial Neoplasms / metabolism
  • [MeSH-minor] Adult. Amino Acids / metabolism. Female. Glucose / metabolism. Glycolysis. Humans. Imaging, Three-Dimensional. Magnetic Resonance Imaging. Male. Methionine / analogs & derivatives. Methionine / pharmacokinetics. Radioactive Tracers. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. GLUCOSE .
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16292175.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Amino Acids; 0 / Radioactive Tracers; AE28F7PNPL / Methionine; BN630929UL / methionine methyl ester; IY9XDZ35W2 / Glucose
  •  go-up   go-down


48. Klink B, Schlingelhof B, Klink M, Stout-Weider K, Patt S, Schrock E: Glioblastomas with oligodendroglial component - common origin of the different histological parts and genetic subclassification. Anal Cell Pathol (Amst); 2010;33(1):37-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastomas with oligodendroglial component - common origin of the different histological parts and genetic subclassification.
  • BACKGROUND: Glioblastomas are the most common and most malignant brain tumors in adults.
  • A small subgroup of glioblastomas contains areas with histological features of oligodendroglial differentiation (GBMO).
  • Our objective was to genetically characterize the oligodendroglial and the astrocytic parts of GBMOs and correlate morphologic and genetic features with clinical data.
  • METHODS: The oligodendroglial and the "classic" glioblastoma parts of 13 GBMO were analyzed separately by interphase fluorescence in situ hybridization (FISH) on paraffin sections using a custom probe set (regions 1p, 1q, 7q, 10q, 17p, 19q, cen18, 21q) and by comparative genomic hybridization (CGH) of microdissected paraffin embedded tumor tissue.
  • RESULTS: We identified four distinct genetic subtypes in 13 GBMOs: an "astrocytic" subtype (9/13) characterized by +7/-10; an "oligodendroglial" subtype with -1p/-19q (1/13); an "intermediate" subtype showing +7/-1p (1/13), and an "other" subtype having none of the former aberrations typical for gliomas (2/13).
  • The different histological tumor parts of GBMO revealed common genetic changes in all tumors and showed additional aberrations specific for each part.
  • CONCLUSION: Our findings demonstrate the monoclonal origin of GBMO followed by the development of the astrocytic and oligodendroglial components.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioblastoma / genetics. Glioblastoma / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Image Processing, Computer-Assisted. Imaging, Three-Dimensional. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20966543.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC4605661
  •  go-up   go-down


49. Inagawa H, Ishizawa K, Hirose T: Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. Acta Cytol; 2007 Nov-Dec;51(6):900-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN: Qualitative analysis of cytologic features of the 3 brain tumors was conducted using intraoperative touch or squash preparations that were stained with the Papanicolaou method, targeting the cellular density, cytoplasmic and nuclear profiles and blood vessel morphology.
  • In addition, we attempted a computer-assisted image analysis of tumor cell nuclei and compared the results with qualitative observations.
  • In both tumors of a higher grade, anaplastic large nuclei and proliferating endothelial cells were noted.
  • Quantitative studies suggested that nuclei of oligodendroglial tumors were significantly rounder than those of astrocytomas.
  • Cytologic as well as histologic assessment should be conducted at the intraoperative diagnosis of these tumors.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Cytodiagnosis / methods. Oligodendroglioma / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Count. Cell Nucleus / pathology. Child. Child, Preschool. Cytoplasm / pathology. Diagnosis, Differential. Female. Humans. Image Processing, Computer-Assisted. Intraoperative Period. Male. Middle Aged


50. Shaw EJ, Haylock B, Husband D, du Plessis D, Sibson DR, Warnke PC, Walker C: Gene expression in oligodendroglial tumors. Anal Cell Pathol (Amst); 2010;33(2):81-94
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression in oligodendroglial tumors.
  • BACKGROUND: Oligodendroglial tumors with 1p/19q loss are more likely to be chemosensitive and have longer survival than those with intact 1p/19q, but not all respond to chemotherapy, warranting investigation of the biological basis of chemosensitivity.
  • METHODS: Gene expression profiling was performed using amplified antisense RNA from 28 oligodendroglial tumors treated with chemotherapy (26 serial stereotactic biopsy, 2 resection).
  • RESULTS: Unsupervised hierarchical clustering showed clustering of multiple samples from the same case in 14/17 cases and identified subgroups associated with tumor grade and 1p/19q status.
  • IQGAP1, INA, TGIF1, NR2F2 and MYCBP were differentially expressed in oligodendroglial tumors with 1p/19q loss.
  • CONCLUSION: Gene expression profiling using serial stereotactic biopsies indicated greater homogeneity within tumors than between tumors.
  • Genes associated with 1p/19q status or response were identified warranting further elucidation of their role in oligodendroglial tumors.
  • [MeSH-major] Astrocytoma / genetics. Brain Neoplasms / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Cluster Analysis. Drug Resistance, Neoplasm / genetics. Female. Gene Expression. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Principal Component Analysis. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Oncol (Dordr). 2011 Aug;34(4):407-8
  • (PMID = 20966545.001).
  • [ISSN] 2210-7185
  • [Journal-full-title] Analytical cellular pathology (Amsterdam)
  • [ISO-abbreviation] Anal Cell Pathol (Amst)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ PMC4605574
  •  go-up   go-down


51. Cui XL, Zhao ZG, Ren XH, Sui DL, Chu JS, Tang K, Zeng C, Lin S: [Characteristics of combining loss of heterozygosity of 1p/19q in glioma]. Zhonghua Wai Ke Za Zhi; 2010 Jun 1;48(11):852-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: The status of 1p and 19q of 138 glioma specimen from January 2009 to December 2009 was evaluated by Fluorescence in situ hybridization (FISH) method, and the frequencies of combining LOH of 1p/19q were compared between different pathologies, brain sub-regions, genders and ages.
  • RESULTS: The frequencies of combined LOH of 1p and 19q of oligodendroglial (81.3%) and oligo astrocytic tumors (55.8%) were significantly higher than that of astrocytic tumor (22.2%) (P < 0.01), and the frequency of oligodendroglial tumor was significantly higher than that of oligo astrocytic tumor (P < 0.05).
  • CONCLUSION: Combining LOH of 1p and 19q has significant correlation with the pathologies and brain sub-regions.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Male. Middle Aged. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21163056.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


52. Idbaih A, Marie Y, Lucchesi C, Pierron G, Manié E, Raynal V, Mosseri V, Hoang-Xuan K, Kujas M, Brito I, Mokhtari K, Sanson M, Barillot E, Aurias A, Delattre JY, Delattre O: BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer; 2008 Apr 15;122(8):1778-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whole chromosomes (chrs) 1p and 19q losses with centromeric breakpoints and EGFR high level amplification were found to be mutually exclusive, permitting identification of 3 distinct, nonoverlapping groups of tumors with striking clinicopathological differences.
  • Type A tumors with chrs 1p and 19q co-deletion exhibited an oligodendroglial phenotype and a longer patient survival.
  • Type B tumors were characterized by EGFR amplification.
  • Finally, type C tumors displayed none of the previous patterns but the presence of chr 7 gain, chr 9p deletion and/or chr 10 loss.
  • It included astrocytic tumors in patients younger than in type B and whose prognosis was highly dependent upon the number of alterations.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosome Deletion. Glioma / genetics. Glioma / pathology. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Chromosomes, Artificial, Bacterial. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 19. Chromosomes, Human, Pair 7. Chromosomes, Human, Pair 9. Disease-Free Survival. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Multivariate Analysis. Nucleic Acid Hybridization. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Oligonucleotides. Predictive Value of Tests. Prognosis. Proportional Hazards Models. Survival Analysis. World Health Organization

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18076069.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oligonucleotides; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


53. Frenel JS, Botti M, Loussouarn D, Campone M: [Prognostic and predictive factors for gliomas in adults]. Bull Cancer; 2009 Apr;96(4):357-67
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas are the most prevalent type of primary brain tumor in adults.
  • Because patients with a same histologic diagnosis have variable outcomes, there is a need to develop better prognostic markers to predict tumor behaviour and response to therapy.
  • For patients with low-grade gliomas, several clinical parameters affect prognosis and therapeutic options: histological type, tumor measurements, young age, performance status.
  • For high-grade tumors, prognostic and predictive molecular markers have been identified.
  • The combined loss of 1p and 19q is strongly correlated with the oligodendroglial phenotype and is associated with both chemotherapeutic response and prolonged overall survival in anaplastic (grade III) oligodendrogliomas treated with PCV chemotherapy and probably with temozolomide.
  • [MeSH-major] Brain Neoplasms. Glioma
  • [MeSH-minor] Adult. Age Factors. Biomarkers, Tumor / metabolism. Chromosome Deletion. Humans. PTEN Phosphohydrolase / metabolism. Predictive Value of Tests. Prognosis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / metabolism. Treatment Outcome. Tumor Burden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19357011.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  • [Number-of-references] 52
  •  go-up   go-down


54. Guillaudeau A, Durand K, Pommepuy I, Robert S, Chaunavel A, Lacorre S, DeArmas R, Bourtoumieux S, El Demery M, Moreau JJ, Labrousse F: Determination of EGFR status in gliomas: usefulness of immunohistochemistry and fluorescent in situ hybridization. Appl Immunohistochem Mol Morphol; 2009 May;17(3):220-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluorescent in situ hybridization (FISH) and immunohistochemistry (IHC) techniques were used to assess EGFR gene amplification and protein abundance in a series of 35 gliomas, including World Health Organization (WHO) grade I, II, and III astrocytomas (AI, AII, AIII), grade II and III tumors with oligodendroglial component (OII, OIII) and grade IV glioblastomas (GBs).
  • EGFR gene amplification was found in one-third of the tumors studied.
  • It was frequent in GB and OIII but was never found in AI, AII, AIII, and OII tumors.
  • IHC and FISH provided similar findings for grade of tumor, despite the fact that, in contrast to the FISH gene amplification, EGFR protein was overexpressed in AIII and in GB.
  • EGFR gene amplification was never observed in tumors not containing EGFR protein: therefore FISH is unnecessary when IHC shows no EGFR protein expression.
  • EGFR gene amplification seems to be restricted to high-grade tumors, WHO grade IV astrocytomas, and grade III oligodendroglial tumors.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19391220.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


55. Gresner SM, Rieske P, Wozniak K, Piaskowski S, Jaskolski DJ, Skowronski W, Golanska E, Sikorska B, Liberski PP: Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender. Clin Neuropathol; 2006 Jan-Feb;25(1):18-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular analysis of chromosome 1, 10 and 19 abnormalities in human oligodendroglial tumors: relationship between frequency of LOH grade, age and gender.
  • BACKGROUND: Loss of heterozygosity (LOH) on 1p and 19q is observed in most oligodendroglial tumors.
  • LOH on 10q appears to be less common in these tumors as compared to other gliomas.
  • PATIENTS AND METHODS: We reviewed 14 patients with oligodendroglial tumors (10 low-grade and 4 anaplastic oligodendroglioma) to evaluate the frequency of LOH on 1p, 10q and 19q and correlate it with tumor grade and patients' age and gender; 5 loci on 1p and 5 on 19q as well as 4 on 10q were analyzed for LOH using PCR techniques.
  • RESULTS: LOH on 1p together with 19q was detected in 6 tumors, 1 tumor showed deletion of 19q accompanied with deletion on 10q.
  • No association between LOH on 1p nor 19q and tumor grade or patients' gender was found.
  • CONCLUSION: Our study provides several clinically interesting findings and further supports the hypothesis of chromosome 1p and 19q involvement in the oligodendroglial cancerogenesis.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Chromosome Aberrations. DNA, Neoplasm / genetics. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Age Factors. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Sex Factors

  • Genetic Alliance. consumer health - Chromosome 10.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465770.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


56. Kuo LT, Kuo KT, Lee MJ, Wei CC, Scaravilli F, Tsai JC, Tseng HM, Kuo MF, Tu YK: Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors. Int J Cancer; 2009 Jun 15;124(12):2872-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation among pathology, genetic and epigenetic profiles, and clinical outcome in oligodendroglial tumors.
  • Recent studies have revealed a correlation between specific genetic changes, such as loss of chromosome 1p and 19q, and sensitivity of oligodendroglial neoplasm to radiotherapy and chemotherapy; epigenetic changes also play an important role in some tumors.
  • In this retrospective study, we analyzed chromosomal alterations in 17 loci and promoter methylation status of 8 tumor-related genes in 49 oligodendroglial tumors (29 WHO grade II and 11 WHO grade III oligodendrogliomas; 7 WHO grade II and 2 WHO grade III oligoastrocytomas) using quantitative microsatellite analysis and methylation-specific polymerase chain reaction and correlated this information with clinical data.
  • Promoter methylation was detected in p14, p15, p16, p53, p73, PTEN, MGMT and RASSF1A genes in 24.5%, 6.1%, 46.9%, 0%, 6.1%, 42.9%, 53.1% and 77.6% of tumors, respectively.
  • Our findings suggest that the frequent deletion and hypermethylation of tumor-related genes may represent a mechanism of tumor development and progression and emphasize the importance of defining new molecular markers for predicting prognosis, tumor recurrence and therapeutic response in cancer management.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosome Aberrations. Chromosomes, Human / genetics. Epigenesis, Genetic. Neoplasm Proteins / genetics. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cell Proliferation. Child. Child, Preschool. DNA Methylation. DNA Modification Methylases / genetics. DNA Modification Methylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / genetics. Female. Humans. Immunoenzyme Techniques. Ki-67 Antigen / metabolism. Male. Microsatellite Repeats. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. Promoter Regions, Genetic / genetics. Retrospective Studies. Survival Rate. Tumor Suppressor Proteins / genetics. Tumor Suppressor Proteins / metabolism. Ubiquitin-Protein Ligases / genetics. Ubiquitin-Protein Ligases / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 UICC.
  • [ErratumIn] Int J Cancer. 2009 Sep 1;125(5):1241
  • (PMID = 19330828.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


57. Kocaeli H, Yakut T, Bekar A, Taşkapilioğlu O, Tolunay S: Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report. Surg Neurol; 2006 Dec;66(6):627-30; discussion 630-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The rate of remote recurrence after surgery for the primary tumor cannot be estimated from the scarce literature, but delayed treatment of the primary tumor and genetic alterations may be associated with this phenomenon.
  • The genetic analysis of the primary and recurrent tumors showed trisomy 7, monosomy 10, but not 1p or 19q deletions, which have been proposed as markers for favorable prognosis.
  • As the genetic analysis suggests, conversion of oligodendroglioma to GBM may be associated with gain of chromosome 7, loss of chromosome 10, and other genetic markers that may represent late events in the oncogenesis of oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / pathology. Frontal Lobe / pathology. Glioblastoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 10 / genetics. Chromosomes, Human, Pair 7 / genetics. Craniotomy. Humans. Magnetic Resonance Imaging. Male. Monosomy / diagnosis. Monosomy / genetics. Neoplasm Invasiveness / pathology. Neoplasm Recurrence, Local. Radiosurgery / instrumentation. Seizures / diagnosis. Seizures / etiology. Trisomy / diagnosis. Trisomy / genetics

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145331.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M: Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res; 2005 Feb 1;11(3):1119-28
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
  • Because most 1p deletions in gliomas involve almost the entire chromosome arm, narrowing the region of the putative tumor suppressor gene has been difficult.
  • EXPERIMENTAL DESIGN: Among 205 consecutive cases of glioma studied for 1p loss of heterozygosity (LOH), 112 tumors were evaluated for both 1p and 19q LOH using at least three polymorphic markers on 1p and 19q each.
  • The latter group included both low-grade tumors (oligodendroglioma, diffuse astrocytoma, and "oligoastrocytoma") and high-grade tumors (anaplastic oligodendrogliomas, anaplastic astrocytomas, anaplastic oligoastrocytomas).
  • Tumors with small segmental 1p losses (defined as LOH at some loci with retention of heterozygosity at other loci) were studied using a more extensive panel of markers to define the 1p MDR.
  • In contrast, no astrocytomas and only 6 of 30 (20%) oligoastrocytic tumors had combined 1p/19q loss.
  • Eleven tumors (6 oligodendrogliomas or having oligodendroglial components, 5 purely astrocytic) with small segmental 1p losses underwent further detailed LOH mapping.
  • All informative tumors in the oligodendroglial group and 2 of 3 informative astrocytomas showed LOH at 1p36.23, with a 150-kb MDR located between D1S2694 and D1S2666, entirely within the CAMTA1 transcription factor gene.
  • CAMTA1 is normally expressed predominantly in non-neoplastic adult brain tissue.
  • Relative to the latter, the expression level of CAMTA1 was low in oligodendroglial tumors and was further halved in cases with 1p deletion compared with those without 1p deletion (Mann-Whitney, P = 0.03).
  • CONCLUSIONS: Our data confirm the strong association of combined 1p/19q loss with classic oligodendroglioma histology and identify a very small segment of 1p36 located within CAMTA1 that was deleted in all oligodendroglial tumors with 1p LOH.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Glioma / genetics. Loss of Heterozygosity
  • [MeSH-minor] Adult. Astrocytoma / genetics. Astrocytoma / pathology. Calcium-Binding Proteins / genetics. Chromosome Deletion. Chromosome Mapping. Expressed Sequence Tags. Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Genes, Tumor Suppressor. Humans. Microsatellite Repeats. Mutation. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Reverse Transcriptase Polymerase Chain Reaction. Trans-Activators / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709179.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CAMTA1 protein, human; 0 / Calcium-Binding Proteins; 0 / Trans-Activators
  •  go-up   go-down


59. Xu M, See SJ, Ng WH, Arul E, Back MF, Yeo TT, Lim CC: Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors. Neurosurgery; 2005 May;56(5):919-26; discussion 919-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of magnetic resonance spectroscopy and perfusion-weighted imaging in presurgical grading of oligodendroglial tumors.
  • OBJECTIVE: Oligodendroglial tumors form an uncommon, but distinct, subgroup of gliomas with longer survival, better treatment response, and characteristic genetic alterations.
  • Noninvasive grading of oligodendroglial tumors using functional and metabolic magnetic resonance imaging may be helpful in guiding the treatment approach and predicting malignant transformation of these tumors.
  • We assessed the ability of tumor contrast enhancement, normalized cerebral blood volume, normalized choline, and the presence of either lactate or lipid metabolites to correctly predict the World Health Organization tumor grade.
  • The accuracy of tumor grading using each method was also compared.
  • RESULTS: Tumor contrast enhancement (P = 0.069) and normalized cerebral blood volume (P = 0.181) were not significantly different between low and high-grade oligodendrogliomas.
  • The MRSI measurement of normalized choline was significantly higher in high-grade (2.82 +/- 0.64) than in low-grade (1.62 +/- 0.46) oligodendrogliomas (P < 0.001), and the presence of lactate or lipid metabolites also correctly predicted high-grade tumors (P = 0.014).
  • CONCLUSION: MRSI measurements are more accurate than perfusion-weighted magnetic resonance imaging or conventional contrast enhancement in differentiating oligodendroglial tumor grade.
  • In these inherently vascular tumors, metabolic measurements of mitosis and necrosis may be better than measures of neovascularity in presurgical grading.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / diagnosis. Oligodendroglioma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Male. Middle Aged. Observer Variation. Preoperative Care. Reproducibility of Results. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854239.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Ren XH, Cui XL, Lin S, Wang ZC: [The correlation between combining 1p/19q LOH and pathology in gliomas]. Zhonghua Yi Xue Za Zhi; 2010 Jul 6;90(25):1781-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumor samples from 127 glioma patients were collected.
  • RESULTS: The frequencies of combining 1p/19q LOH in astrocytic, oligoastrocytic and oligodendroglial tumors were 19.30%, 50.00% and 80.77% respectively.
  • The frequencies of combining 1p/19q LOH in oligoastrocytic and oligodendroglial tumors were higher than those in astrocytic tumors (P < 0.01) and the frequencies of combining 1p/19q LOH in oligodendroglial tumors was higher than those in oligoastrocytic tumors (P < 0.05).
  • The frequencies of 1p/19q LOH in astrocytic, oligoastrocytic and oligodendroglial tumors were 12.28%, 11.36 and 0 respectively.
  • It is significantly correlated with oligodendroglial component.
  • Combining 1p/19q LOH may be valuable in the diagnosis, treatment and prognostic prediction for glioma with oligodendroglial component.
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Female. Humans. Male. Middle Aged. Oligodendroglia / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979900.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


61. Jeuken JW, van der Maazen RW, Wesseling P: Molecular diagnostics as a tool to personalize treatment in adult glioma patients. Technol Cancer Res Treat; 2006 Jun;5(3):215-29
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular diagnostics as a tool to personalize treatment in adult glioma patients.
  • Gliomas, the most frequent primary brain tumors in humans, form a heterogeneous group, encompassing many different histological types and malignancy grades.
  • The major representatives in this subgroup are the diffuse astrocytic, oligodendroglial, and mixed oligo-astrocytic tumors.
  • After summarizing the most relevant genetic aberrations and pathways in these tumors detected up till now, this review will discuss the clinical relevance of this information.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Glioma / genetics. Molecular Diagnostic Techniques
  • [MeSH-minor] Cell Cycle Proteins / genetics. DNA Methylation. DNA Repair. Gene Dosage. Humans. Neovascularization, Pathologic. Receptor Protein-Tyrosine Kinases / genetics. Retinoblastoma Protein / genetics. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700618.001).
  • [ISSN] 1533-0346
  • [Journal-full-title] Technology in cancer research & treatment
  • [ISO-abbreviation] Technol. Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins; 0 / Retinoblastoma Protein; 0 / Tumor Suppressor Protein p53; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases
  • [Number-of-references] 94
  •  go-up   go-down


62. Hergersberg M, Mariani L, Vassella E, Murtin C, Weis J, Moschopulos M, Laeng H, Landolt H, Huber A, Roelcke U: Age at diagnosis and loss of heterozygosity on chromosome 1p and 19q in oligodendroglial tumors. J Neurooncol; 2006 Nov;80(2):215-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Age at diagnosis and loss of heterozygosity on chromosome 1p and 19q in oligodendroglial tumors.
  • The age distribution and incidence of loss of heterozygosity (LOH) of 1p and 19q was analyzed in 85 oligodendroglial tumors WHO II and III.
  • The peak of tumor manifestation was in the age group of 35 to 55 years.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Loss of Heterozygosity / genetics. Oligodendroglioma / diagnosis. Oligodendroglioma / genetics
  • [MeSH-minor] Adult. Age of Onset. Aging / physiology. Female. Humans. Male. Middle Aged. O(6)-Methylguanine-DNA Methyltransferase / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2005 Jan 20;113(3):379-85 [15455350.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Oct;56(10):1098-104 [9329453.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 [15977639.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2076-84 [11956268.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7683-8 [11606412.001]
  • [Cites] Acta Neuropathol. 2004 Jul;108(1):49-56 [15118874.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1634-42 [15990862.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jan;64(1):10-4 [15715080.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Neurology. 1999 Mar 10;52(4):867-9 [10078745.001]
  • [Cites] Clin Cancer Res. 2004 Jan 1;10(1 Pt 1):228-33 [14734474.001]
  • (PMID = 16685464.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


63. Spampinato MV, Smith JK, Kwock L, Ewend M, Grimme JD, Camacho DL, Castillo M: Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors. AJR Am J Roentgenol; 2007 Jan;188(1):204-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral blood volume measurements and proton MR spectroscopy in grading of oligodendroglial tumors.
  • OBJECTIVE: The purpose of this study was to determine whether perfusion-weighted imaging (PWI) and proton MR spectroscopy (MRS) are useful in differentiating high- and low-grade oligodendroglial tumors.
  • MATERIALS AND METHODS: PWI and MRS studies of 22 patients with histologically proven oligodendroglioma or oligoastrocytoma (13 low-grade and nine anaplastic tumors) were retrospectively reviewed.
  • RESULTS: Relative cerebral blood volume ratios were significantly different (p = 0.004) between low-grade (1.61 +/- 1.20) and high-grade tumors (5.45 +/- 1.96).
  • The optimal relative cerebral blood volume ratio cutoff value in identification of anaplastic oligodendroglial tumors was 2.14.
  • Analysis of MRS data showed significantly higher Cho/Cr ratios (p = 0.002) in high-grade than in low-grade tumors.
  • A Cho/Cr ratio cutoff value of 2.33 had the highest accuracy in identification of high-grade tumors.
  • CONCLUSION: Relative cerebral blood volume measurement and MRS are helpful in differentiating low-grade from anaplastic oligodendroglial tumors.
  • [MeSH-major] Blood Volume. Brain Neoplasms / diagnosis. Diagnosis, Computer-Assisted / methods. Magnetic Resonance Spectroscopy / methods. Oligodendroglioma / diagnosis. Protons
  • [MeSH-minor] Adult. Aged. Blood Volume Determination / methods. Female. Humans. Male. Middle Aged. Reproducibility of Results. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17179366.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


64. Stege EM, Kros JM, de Bruin HG, Enting RH, van Heuvel I, Looijenga LH, van der Rijt CD, Smitt PA, van den Bent MJ: Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer; 2005 Feb 15;103(4):802-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
  • BACKGROUND: Anaplastic oligodendroglioma (OD) tumors, especially those with the combined loss of the short arm of chromosome 1 (1p) and the long arm of chromosome 19 (19q), are sensitive to chemotherapy.
  • METHODS: Two groups of patients were studied: newly diagnosed patients with large OD and mixed oligoastrocytomas (OA) and patients with recurrent OD and OA after radiotherapy who still showed nonenhancing tumors.
  • RESULTS: Three of five patients with recurrent tumors responded.
  • Several patients showed a signficant clinical improvement despite only a modest improvement of the tumor on the MRI scans.
  • CONCLUSIONS: Newly diagnosed patients with OD tumors, with or without loss of 1p/19q, responded to PCV chemotherapy.
  • Up-front chemotherapy may be indicated especially for patients with large tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Astrocytoma / drug therapy. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Lomustine / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Polymerase Chain Reaction. Procarbazine / therapeutic use. Retrospective Studies. Tumor Suppressor Protein p53 / genetics. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 American Cancer Society.
  • (PMID = 15637687.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Tumor Suppressor Protein p53; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


65. Brandes AA, Tosoni A, Cavallo G, Reni M, Franceschi E, Bonaldi L, Bertorelle R, Gardiman M, Ghimenton C, Iuzzolino P, Pession A, Blatt V, Ermani M, GICNO: Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study. J Clin Oncol; 2006 Oct 10;24(29):4746-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: TMZ is active in anaplastic oligodendroglial tumors treated at first recurrence.
  • [MeSH-major] Antineoplastic Agents, Alkylating / pharmacology. Brain Neoplasms / drug therapy. Brain Neoplasms / genetics. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Dacarbazine / analogs & derivatives. O(6)-Methylguanine-DNA Methyltransferase / genetics. Oligodendroglioma / drug therapy. Oligodendroglioma / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Chromosome Deletion. DNA Methylation. DNA Repair. Female. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Promoter Regions, Genetic. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Oligodendroglioma.
  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16954518.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


66. Phi JH, Park SH, Kim SK, Paek SH, Kim JH, Lee YJ, Cho BK, Park CK, Lee DH, Wang KC: Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway. Am J Surg Pathol; 2008 Jan;32(1):103-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway.
  • Moreover, it was recently found that brain tumors contain stem cells that resemble normal neuroglial stem cells in many respects.
  • This study was undertaken to describe Sox2 expression in various brain tumors, and to determine whether Sox2 expression is a universal feature of brain tumors, or whether its expression is limited to a specific lineage of brain tumors.
  • Sox2 immunohistochemistry was performed on 194 brain tumor tissues of various kinds.
  • Fetal and adult normal brain tissues obtained by autopsy and brain tissues of epilepsy patients with cortical dysplasia were used as controls.
  • Sox2 was found to be expressed in various glial tumors, including those with astroglial, oligodendroglial, and ependymal lineages, and in the glial components of mixed neuroglial tumors, regardless of pathologic grade.
  • In brain tumors of embryonal origin, supratentorial primitive neuroectodermal tumors showed robust Sox2 expression, whereas medulloblastomas and pineoblastomas did not.
  • The majority of Sox2-positive tumor cells coexpressed glial fibrillary acidic protein, and most Sox2-negative cells in medulloblastomas and pineoblastomas showed neuronal differentiation.
  • This study suggest that Sox2 may be a tumor marker of glial lineages rather than a universal brain tumor stem cell marker, because its expression pattern was found to correspond to differentiation pathways.
  • On the other hand, the aberrant coexpressions of Sox2 and of a neuronal marker were widely observed in glioblastomas, which reflects a disorganized differentiation pattern that characterizes highly malignant tumors.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. HMGB Proteins / biosynthesis. Neuroglia / cytology. Neuroglia / metabolism. Transcription Factors / biosynthesis
  • [MeSH-minor] Brain / cytology. Brain / embryology. Brain / metabolism. Cell Differentiation. Cell Lineage. Fluorescent Antibody Technique. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. SOXB1 Transcription Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18162777.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / HMGB Proteins; 0 / RNA, Messenger; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


67. Guillaume DJ, Doolittle ND, Gahramanov S, Hedrick NA, Delashaw JB, Neuwelt EA: Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study. Neurosurgery; 2010 Jan;66(1):48-58; discussion 58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.
  • OBJECTIVE: Refractory anaplastic oligodendroglioma and oligoastrocytoma tumors are challenging to treat.
  • This trial primarily evaluated toxicity and estimated the maximum tolerated dose of intra-arterial (IA) melphalan, IA carboplatin, and intravenous (IV) etoposide phosphate in conjunction with blood-brain barrier disruption in these tumors.
  • METHODS: Thirteen patients with temozolomide-refractory anaplastic oligodendroglioma (11 patients) or oligoastrocytoma (2 patients) underwent blood-brain barrier disruption with carboplatin (IA, 200 mg/m(2)/d), etoposide phosphate (IV, 200 mg/m(2)/d), and melphalan (IA, dose escalation) every 4 weeks, for up to 1 year.
  • CONCLUSION: In patients with anaplastic oligodendroglioma or oligoastrocytoma tumors in whom temozolomide treatment has failed, osmotic blood-brain barrier disruption with IA carboplatin, IV etoposide phosphate, and IA melphalan (4 mg/m(2)/d for 2 days) shows acceptable toxicity and encouraging efficacy, especially in patients demonstrating 1p and/or 19q deletion.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1980 Jul;7(1):36-43 [6774280.001]
  • [Cites] J Pharmacol Exp Ther. 1981 Nov;219(2):281-6 [7288620.001]
  • [Cites] Br J Cancer. 1982 Jan;45(1):86-94 [7037033.001]
  • [Cites] J Biol Chem. 1982 Nov 25;257(22):13704-12 [6128339.001]
  • [Cites] Cancer Res. 1983 Feb;43(2):917-20 [6681533.001]
  • [Cites] Cancer. 1984 Sep 15;54(6 Suppl):1160-7 [6467147.001]
  • [Cites] J Neurosurg. 1985 Dec;63(6):876-80 [2997415.001]
  • [Cites] Neurol Clin. 1985 Nov;3(4):831-42 [3908898.001]
  • [Cites] Biochem Pharmacol. 1987 Jan 1;36(1):147-53 [3801051.001]
  • [Cites] J Neurosurg. 1988 Jun;68(6):917-9 [2836567.001]
  • [Cites] J Neurosurg. 1989 Mar;70(3):371-8 [2536804.001]
  • [Cites] J Clin Oncol. 1989 Jul;7(7):904-11 [2738624.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):583-8 [2319317.001]
  • [Cites] J Neurosurg. 1991 May;74(5):763-72 [1849555.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):860-4 [1849986.001]
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1580-90 [1875220.001]
  • [Cites] Anticancer Res. 1991 Nov-Dec;11(6):2231-7 [1776864.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1220-3 [1310889.001]
  • [Cites] J Clin Oncol. 1992 Mar;10(3):452-8 [1311026.001]
  • [Cites] Neurosurgery. 1992 Feb;30(2):223-7 [1312230.001]
  • [Cites] J Neurosurg. 1992 May;76(5):772-81 [1564540.001]
  • [Cites] Neurosurgery. 1992 Apr;30(4):512-6; discussion 516-7 [1316564.001]
  • [Cites] Surg Neurol. 1994 Jan;41(1):19-27 [8310382.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Neurosurgery. 1994 Sep;35(3):378-88; discussion 388 [7800129.001]
  • [Cites] Am J Pathol. 1995 Feb;146(2):436-49 [7856753.001]
  • [Cites] Lancet. 1995 Apr 22;345(8956):1008-12 [7723496.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1786-99 [7602368.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2099-106 [7554060.001]
  • [Cites] Neurosurgery. 1995 Jul;37(1):17-27; discussion 27-8 [8587686.001]
  • [Cites] J Clin Oncol. 1996 Feb;14(2):382-8 [8636747.001]
  • [Cites] J Neurooncol. 1996 Mar;27(3):251-8 [8847559.001]
  • [Cites] Neurosurgery. 1996 Jul;39(1):125-33; discussion 133-4 [8805148.001]
  • [Cites] Cancer Res. 1997 Mar 15;57(6):1129-36 [9067283.001]
  • [Cites] J Neurosurg. 1997 Apr;86(4):603-9 [9120622.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 May 1;38(2):263-71 [9226312.001]
  • [Cites] J Neurooncol. 1997 Nov;35(2):121-31 [9266448.001]
  • [Cites] Int J Oncol. 1998 Apr;12(4):871-82 [9499449.001]
  • [Cites] Neurosurgery. 2004 Jan;54(1):131-40; discussion 141-2 [14683550.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):807-13 [14770438.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1213-20 [15022289.001]
  • [Cites] Hear Res. 2004 Jul;193(1-2):25-30 [15219317.001]
  • [Cites] Leuk Lymphoma. 2007 Sep;48(9):1712-20 [17786706.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):1089-109, ix-x [17964027.001]
  • [Cites] Lancet Neurol. 2008 Jan;7(1):84-96 [18093565.001]
  • [Cites] Clin Cancer Res. 2008 Jan 15;14(2):533-40 [18223229.001]
  • [Cites] J Clin Oncol. 2006 Oct 10;24(29):4746-53 [16954518.001]
  • [Cites] Neurosurg Focus. 2006;21(5):E11 [17134113.001]
  • [Cites] J Neurooncol. 2007 Jan;81(1):81-91 [16858513.001]
  • [Cites] J Clin Oncol. 2007 Jun 1;25(16):2295-305 [17538176.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1145-51 [17284616.001]
  • [Cites] Cancer. 2008 Feb 1;112(3):581-8 [18072268.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Jul;62(2):235-41 [17909806.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):187-93 [18458821.001]
  • [Cites] J Neurooncol. 2008 Sep;89(2):231-8 [18480965.001]
  • [Cites] Surg Oncol Clin N Am. 2008 Oct;17(4):919-33, xi [18722926.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3503-9 [19451444.001]
  • [Cites] J Pharmacol Exp Ther. 2001 Mar;296(3):797-805 [11181909.001]
  • [Cites] Neurosurgery. 2000 Jan;46(1):51-60; discussion 60-1 [10626935.001]
  • [Cites] Cancer. 2000 Feb 1;88(3):637-47 [10649259.001]
  • [Cites] Clin Cancer Res. 2000 Jan;6(1):309-15 [10656463.001]
  • [Cites] Neurosurgery. 2000 Mar;46(3):704-9 [10719867.001]
  • [Cites] J Neurosurg. 2000 Apr;92(4):599-605 [10761648.001]
  • [Cites] Clin Cancer Res. 2001 Mar;7(3):493-500 [11297239.001]
  • [Cites] Neurosurgery. 2001 May;48(5):1033-40; discussion 1040-1 [11334269.001]
  • [Cites] J Clin Oncol. 2001 Jul 15;19(14):3333-9 [11454880.001]
  • [Cites] Curr Neurol Neurosci Rep. 2002 May;2(3):216-24 [11937000.001]
  • [Cites] J Neurooncol. 2002 Jan;56(2):183-8 [11995820.001]
  • [Cites] AJNR Am J Neuroradiol. 2002 Nov-Dec;23(10):1807-10 [12427643.001]
  • [Cites] J Clin Oncol. 2003 Jun 15;21(12):2305-11 [12805331.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1727-31 [14630676.001]
  • [Cites] Surgery. 2004 Aug;136(2):210-8 [15300182.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):904-6 [15365146.001]
  • [Cites] Cancer Treat Rep. 1977 Jul;61(4):519-26 [884689.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1083-99; discussion 1099-100 [9588554.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1549-55 [9626476.001]
  • [Cites] Int J Oncol. 1998 Sep;13(3):537-42 [9683790.001]
  • [Cites] Neurosurgery. 1998 Oct;43(4):879-86; discussion 886-9 [9766316.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] Neurosurgery. 1998 Nov;43(5):1066-73 [9802850.001]
  • [Cites] Anesth Analg. 1999 Mar;88(3):559-67 [10072006.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Feb;26(2):258-65 [15709122.001]
  • [Cites] Pediatr Blood Cancer. 2005 Aug;45(2):222-5 [15770640.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Sep;314(3):1052-8 [15951398.001]
  • [Cites] J Neurooncol. 2006 May;77(3):279-84 [16314949.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] Cancer J Sci Am. 1996 May-Jun;2(3):166-74 [9166517.001]
  • (PMID = 20023537.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS053468; United States / NINDS NIH HHS / NS / NS34608; United States / NINDS NIH HHS / NS / R01 NS053468-03; United States / NINDS NIH HHS / NS / NS044687-26; United States / NINDS NIH HHS / NS / R01 NS034608; United States / NCI NIH HHS / CA / CA137488; United States / NINDS NIH HHS / NS / R37 NS044687-26; United States / NINDS NIH HHS / NS / R37 NS044687; United States / NINDS NIH HHS / NS / NS053468-03; United States / NINDS NIH HHS / NS / NS44687; United States / NCI NIH HHS / CA / R01 CA137488-15; United States / NCI NIH HHS / CA / CA137488-15; United States / NINDS NIH HHS / NS / R01 NS044687; United States / NCI NIH HHS / CA / R01 CA137488
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cross-Linking Reagents; 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; BG3F62OND5 / Carboplatin; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ NIHMS161269; NLM/ PMC2806091
  •  go-up   go-down


68. Tanaka S, Akimoto J, Kobayashi I, Oka H, Ujiie H: Individual adjuvant therapy for malignant gliomas based on O6-methylguanine-DNA methyltransferase messenger RNA quantitation by real-time reverse-transcription polymerase chain-reaction. Oncol Rep; 2008 Jul;20(1):165-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immediately after the operation, mRNA expression for drug-resistance genes was investigated in frozen samples of malignant gliomas from 55 patients (30 glioblastoma multiformes, 20 anaplastic astrocytomas and 5 anaplastic oligodendroglial tumors) by real-time quantitative RT-PCR with specific primers for MGMT.
  • Thirteen patients, whose tumors had an RQV of >1.0 or who had an absolute value of MGMT of >6.0x10(3) copies/microg RNA, were treated by platinum-based chemotherapy using cisplatin or carboplatin.
  • The response rate was 40.9% for glioblastoma multiformes, 60.0% for anaplastic astrocytomas and 80.0% for anaplastic oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / therapy. Glioma / therapy. O(6)-Methylguanine-DNA Methyltransferase / genetics. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction / methods
  • [MeSH-minor] Adult. Combined Modality Therapy. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Evidence-Based Medicine. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575733.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


69. Takeuchi H, Kubota T, Kitai R, Matsuda K, Hashimoto N, Sato K: Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component. J Neurooncol; 2009 Jan;91(1):33-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosome 1p and 19q deletions in malignant glioneuronal tumors with oligodendroglioma-like component.
  • Malignant glioneuronal tumors (MGNT) are suggested to be a new entity of glioma defined morphologically as any malignant glioma showing immunohistoichemical evidence of neuronal differentiation.
  • We encountered seven cases of MGNT with oligodendroglioma-like component and investigated alternations of chromosome 1p and 19q in these tumors.
  • Immunohistochemical study of these tumors was performed using neuronal markers (synaptophysin, neurofilament, beta-tubulin, chromogranin A and NeuN), astrocytic marker (GFAP) and Ki-67.
  • We undertook a molecular cytogenetic study of tumor specimens obtained from seven patients using fluorescence in situ hybridization (FISH) with DNA probes mapping to chromosome 1p36, 1q25, 19p13 and 19q13.
  • Histologically, these tumors resembled anaplastic oligodendroglioma.
  • Immunohistochemically, tumor cells were immunoreactive for synaptophysin (7/7), neurofilament (6/7), beta-tubulin (5/7), chromogranin A (4/7), NeuN (2/7) and GFAP (7/7).
  • 1p and 19q deletions were present in MGNT, especially those with oligodendroglial components.
  • We suggest that the oligodendroglial-like feature was associated with not only 1p or 19q loss but also differentiation along neuronal cell lines as a factor of favorable prognosis in glial tumors.
  • [MeSH-major] Brain Neoplasms / metabolism. Chromosome Deletion. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Oligodendroglioma / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Nerve Tissue Proteins / metabolism. Oligodendroglia / metabolism. Oligodendroglia / pathology

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):275-81 [7522542.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71 [11556543.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Aug;24(4):302-8 [9775396.001]
  • [Cites] J Histochem Cytochem. 1996 Oct;44(10):1167-71 [8813082.001]
  • [Cites] Brain Dev. 1998 Mar;20(2):88-94 [9545178.001]
  • [Cites] Hum Pathol. 2004 Sep;35(9):1156-9 [15343519.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10 ):1171-83 [9777979.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] Histopathology. 2006 Mar;48(4):438-44 [16487366.001]
  • [Cites] Glycoconj J. 1996 Jun;13(3):433-43 [8781974.001]
  • [Cites] Oncogene. 1999 Jul 15;18(28):4144-52 [10435596.001]
  • [Cites] Am J Surg Pathol. 2001 Oct;25(10):1252-60 [11688459.001]
  • [Cites] Int J Cancer. 1995 Jun 22;64(3):207-10 [7622310.001]
  • [Cites] Neurosurgery. 2004 Dec;55(6):1377-91: discussion 1391-2 [15574220.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neurosurg. 2000 Jun;92(6):983-90 [10839259.001]
  • [Cites] Am J Surg Pathol. 1997 Feb;21(2):206-12 [9042288.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Adv Anat Pathol. 2001 Jul;8(4):183-99 [11444508.001]
  • [Cites] Acta Neuropathol. 2001 Apr;101(4):311-20 [11355302.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Aug;31(4):429-38 [16008827.001]
  • [Cites] Acta Neuropathol. 1986;72(1):15-22 [2435103.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1204-12 [2205356.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Nov;61(11):947-55 [12430711.001]
  • [Cites] J Clin Neurosci. 1998 Oct;5(4):466-9 [18639083.001]
  • [Cites] Acta Neuropathol. 1998 May;95(5):493-504 [9600596.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 Jan;54(1):91-5 [7815084.001]
  • (PMID = 18781279.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Nerve Tissue Proteins
  •  go-up   go-down


70. Scopece L, Franceschi E, Cavallo G, Paioli A, Paioli G, Conforti R, Palmerini E, Berzioli C, Spagnolli F, Esposti RD, Crinò L: Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors. J Neurooncol; 2006 Sep;79(3):299-305
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carboplatin and etoposide (CE) chemotherapy in patients with recurrent or progressive oligodendroglial tumors.
  • BACKGROUND: Oligodendroglial tumors are rare and chemosensitive diseases; but the overall results with current chemotherapy regimens cannot be considered satisfactory and other active treatments are necessary.
  • METHODS: In this phase II trial we evaluated the response rate of first or second line CE regimen (Carboplatin AUC 5 on day 1 and Etoposide 120 mg/m2 on days 1-3 every 28 days) in patients with recurrent/progressive oligodendroglial tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Brain Neoplasms / drug therapy. Glioma / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Aged. Carboplatin / administration & dosage. Carboplatin / adverse effects. Disease-Free Survival. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Loss of Heterozygosity. Male. Middle Aged. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 1996 Feb;27(2):149-55 [8699237.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):249-54 [2086739.001]
  • [Cites] J Surg Oncol. 1999 Jul;71(3):167-70 [10404133.001]
  • [Cites] Med Pediatr Oncol. 1998 Jul;31(1):16-8 [9607424.001]
  • [Cites] J Neurosurg. 1996 Oct;85(4):597-601 [8814162.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] J Clin Oncol. 2001 May 1;19(9):2449-55 [11331324.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Neurology. 1998 Oct;51(4):1140-5 [9781544.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1727-31 [14630676.001]
  • [Cites] Cancer. 2004 Nov 1;101(9):2079-85 [15372474.001]
  • [Cites] J Neurooncol. 1991 Oct;11(2):165-70 [1744684.001]
  • [Cites] Ann Oncol. 2003 Apr;14 (4):599-602 [12649108.001]
  • [Cites] Br J Cancer. 2004 Sep 13;91(6):1038-44 [15305187.001]
  • [Cites] J Clin Oncol. 1984 Mar;2(3):215-20 [6321690.001]
  • [Cites] Cancer Chemother Pharmacol. 1992;29(5):339-42 [1312906.001]
  • [Cites] J Clin Oncol. 1992 Jul;10(7):1074-7 [1318951.001]
  • (PMID = 16645720.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin
  •  go-up   go-down


71. Min HS, Kim B, Park SH: Array-based comparative genomic hybridization and immunohistochemical studies in gliomatosis cerebri. J Neurooncol; 2008 Dec;90(3):259-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gliomatosis cerebri (GC) are extensively infiltrative glial tumors classified as astrocytic tumors in the current World Health Organization (WHO) classification scheme.
  • In histological and immunohistochemical review, 18 cases (64%) were of astrocytic lineage, three (11%) were of oligodendroglial lineage, and seven (25%) were of uncommitted lineage.
  • These altered genetic foci are not known to be involved in the development of conventional glial tumors, including astrocytic tumors.
  • In conclusion, despite the dominant astrocytic differentiation of GC histologically, novel genomic aberrations found in our GC cases were different from those of astrocytic tumors.
  • [MeSH-minor] Adolescent. Adult. Aged. Antigens, CD34 / metabolism. Child. Child, Preschool. Cluster Analysis. DNA Modification Methylases / metabolism. DNA Repair Enzymes / metabolism. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Infant. Infant, Newborn. Intermediate Filament Proteins / metabolism. Male. Middle Aged. Nerve Tissue Proteins / metabolism. Nestin. Receptor, Epidermal Growth Factor / metabolism. Retrospective Studies. Survival Analysis. Tumor Suppressor Proteins / metabolism. Young Adult

  • Genetic Alliance. consumer health - Gliomatosis Cerebri.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2005 Apr;72 (2):115-22 [15925990.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):207-11 [9771718.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Sep;61(9):806-14 [12230327.001]
  • [Cites] Hum Pathol. 1997 Oct;28(10):1166-79 [9343324.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(8):755-62 [9810441.001]
  • [Cites] Nat Genet. 2005 Jun;37 Suppl:S11-7 [15920524.001]
  • [Cites] Acta Neurochir (Wien). 2000;142(4):469-72 [10883346.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):201-5 [16200347.001]
  • [Cites] Bioinformatics. 2005 Mar;21(6):821-2 [15531610.001]
  • [Cites] Neurosurgery. 2003 Aug;53(2):261-71; discussion 271 [12925240.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):23-7 [16955219.001]
  • [Cites] Genes Chromosomes Cancer. 1995 Oct;14(2):149-53 [8527397.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 May;83(9):2934-8 [3458254.001]
  • [Cites] Nucleic Acids Res. 2002 Feb 15;30(4):e15 [11842121.001]
  • [Cites] Ann Neurol. 2002 Oct;52(4):390-9 [12325066.001]
  • [Cites] Acta Neuropathol. 2003 Jun;105(6):529-36 [12734658.001]
  • [Cites] Clin Genet. 2004 Dec;66(6):488-95 [15521975.001]
  • [Cites] Acta Neuropathol. 2005 Dec;110(6):527-36 [16222524.001]
  • [Cites] Hum Pathol. 2003 Jan;34(1):102-6 [12605375.001]
  • [Cites] J Neurooncol. 2003 Jan;61(1):1-5 [12587789.001]
  • [Cites] Lab Invest. 2006 Sep;86(9):968-78 [16751780.001]
  • (PMID = 18704270.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


72. Tejada S, Lobo MV, García-Villanueva M, Sacristán S, Pérez-Morgado MI, Salinas M, Martín ME: Eukaryotic initiation factors (eIF) 2alpha and 4E expression, localization, and phosphorylation in brain tumors. J Histochem Cytochem; 2009 May;57(5):503-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eukaryotic initiation factors (eIF) 2alpha and 4E expression, localization, and phosphorylation in brain tumors.
  • One or both of these factors are often overexpressed in several types of cancer cells; however, no data are available at present regarding eIF4E and eIF2alpha levels in brain tumors.
  • In this study, we analyzed the expression, subcellular localization and phosphorylation states of eIF4E and eIF2alpha in 64 brain tumors (26 meningiomas, 16 oligodendroglial tumors, and 22 astrocytomas) and investigated the correlation with the expression of MIB-1, p53, and cyclin D1 proteins as well.
  • There are significant differences in the phosphorylated eIF4E levels between the tumors studied, being the highest in meningiomas and the lowest in the oligodendroglial tumors.
  • Relative to subcellular localization, eIF4E is frequently found in the nucleus of the oligodendroglial tumors and rarely in the same compartment of the meningiomas, whereas eIF2alpha showed an inverse pattern.
  • The different expression, phosphorylation, or/and subcellular distribution of eIF2alpha and eIF4E within the brain types of tumors studied could indicate that different pathways are activated for promoting cell cycle proliferation, for instance, leading to increased cyclin D1 expression.
  • [MeSH-major] Brain Neoplasms / metabolism. Eukaryotic Initiation Factor-2 / metabolism. Eukaryotic Initiation Factor-4E / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Cyclin D1 / metabolism. Female. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Phosphorylation. Tumor Suppressor Protein p53 / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 2000 Feb;156(2):425-32 [10666371.001]
  • [Cites] J Clin Neurosci. 2005 Feb;12(2):166-8 [15749420.001]
  • [Cites] Histochem J. 2000 Mar;32(3):139-50 [10841309.001]
  • [Cites] Pathol Res Pract. 2000;196(7):483-8 [10926326.001]
  • [Cites] Biochem J. 2000 Oct 15;351 Pt 2:327-34 [11023817.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2164-71 [11596034.001]
  • [Cites] Mol Cell. 2000 Nov;6(5):1099-108 [11106749.001]
  • [Cites] Cell. 2002 Feb 22;108(4):545-56 [11909525.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Apr;6(4):318-27 [15803138.001]
  • [Cites] J Cell Biol. 2005 Apr 25;169(2):245-56 [15837800.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):178-83 [15894932.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4215-24 [15961768.001]
  • [Cites] Cell Cycle. 2007 Jan 1;6(1):65-9 [17245113.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):234-41 [17284108.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):355-8 [17240151.001]
  • [Cites] Nat Rev Genet. 2007 Jul;8(7):533-43 [17572691.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Genes Dev. 2007 Dec 15;21(24):3232-7 [18055695.001]
  • [Cites] Oncogene. 2008 Mar 6;27(11):1645-9 [17828301.001]
  • [Cites] Cell Cycle. 2008 Mar 1;7(5):553-5 [18256539.001]
  • [Cites] Cell Mol Neurobiol. 2008 Sep;28(6):907-13 [18379871.001]
  • [Cites] Differentiation. 2002 Mar;70(1):10-22 [11963652.001]
  • [Cites] Thyroid. 2001 Dec;11(12):1101-7 [12186496.001]
  • [Cites] Eur J Biochem. 2002 Nov;269(22):5350-9 [12423333.001]
  • [Cites] Oncogene. 2002 Dec 12;21(57):8741-8 [12483527.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3189-99 [15094768.001]
  • [Cites] Oncogene. 2004 Apr 19;23(18):3230-47 [15094773.001]
  • [Cites] Pathol Int. 2004 Jun;54(6):387-91 [15144396.001]
  • [Cites] Cell Tissue Res. 2004 Jun;316(3):369-76 [15127288.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Aug 3;101(31):11269-74 [15277680.001]
  • [Cites] Nat Rev Mol Cell Biol. 2004 Oct;5(10):827-35 [15459663.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Science. 1992 Sep 18;257(5077):1685-9 [1382315.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2736-9 [8504413.001]
  • [Cites] Cell. 1994 Nov 18;79(4):573-82 [7954824.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1065-70 [8577715.001]
  • [Cites] Cancer Res. 1996 Oct 1;56(19):4382-6 [8813130.001]
  • [Cites] Neuropathol Appl Neurobiol. 1996 Aug;22(4):311-6 [8875465.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 Feb;56(2):180-5 [9034372.001]
  • [Cites] Acta Neuropathol. 1998 Feb;95(2):131-5 [9498046.001]
  • [Cites] Neuropathol Appl Neurobiol. 1998 Oct;24(5):381-8 [9821169.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jan;31(1):1-23 [10216939.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jan;31(1):73-86 [10216945.001]
  • [Cites] Am J Pathol. 1999 Jul;155(1):247-55 [10393856.001]
  • [Cites] Endocrinology. 2004 Dec;145(12):5439-47 [15331580.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8639-42 [15574771.001]
  • [Cites] Int J Biochem Cell Biol. 2000 Jun;32(6):633-42 [10785360.001]
  • (PMID = 19188486.001).
  • [ISSN] 0022-1554
  • [Journal-full-title] The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society
  • [ISO-abbreviation] J. Histochem. Cytochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Eukaryotic Initiation Factor-2; 0 / Eukaryotic Initiation Factor-4E; 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1
  • [Other-IDs] NLM/ PMC2675073
  •  go-up   go-down


73. Hatakeyama T, Kawai N, Nishiyama Y, Yamamoto Y, Sasakawa Y, Ichikawa T, Tamiya T: 11C-methionine (MET) and 18F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging; 2008 Nov;35(11):2009-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The purpose of this prospective study was to clarify the individual and combined role of L-methyl-(11)C-methionine-positron emission tomography (MET-PET) and 3'-deoxy-3'-[(18)F]fluorothymidine (FLT)-PET in tumor detection, noninvasive grading, and assessment of the cellular proliferation rate in newly diagnosed histologically verified gliomas of different grades.
  • MET and FLT uptakes were assessed by standardized uptake value of the tumor showing the maximum uptake (SUV(max)), and the ratio to uptake in the normal brain parenchyma (T/N ratio).
  • All tumors were graded by the WHO grading system using surgical specimens, and the proliferation activity of the tumors were determined by measuring the Ki-67 index obtained by immunohistochemical staining.
  • RESULTS: On semiquantitative analysis, MET exhibited a slightly higher sensitivity (87.8%) in tumor detection than FLT (83.3%), and both tracers were 100% sensitive for malignant gliomas.
  • Although the difference of MET SUV(max) and T/N ratio between grades II and IV gliomas was statistically significant (P < 0.001), there was a significant overlap of MET uptake in the tumors.
  • Low-grade gliomas with oligodendroglial components had relatively high MET uptake.
  • Total FLT uptake in the tumor had a higher correlation (r = 0.89, P < 0.001) with Ki-67 proliferation index than MET uptake (r = 0.49, P < 0.01).
  • CONCLUSIONS: PET studies using MET and FLT are useful for tumor detection in newly diagnosed gliomas.
  • However, there is no complimentary information in tumor detection with simultaneous measurements of MET- and FLT-PET in low grade gliomas.
  • FLT-PET seems to be superior than MET-PET in noninvasive tumor grading and assessment of proliferation activity in gliomas of different grades.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carbon Radioisotopes / chemistry. Cell Proliferation. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Male. Middle Aged. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Glioma.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 1993 Jul-Aug;17 (4):660-1 [8331242.001]
  • [Cites] Cancer. 2001 Sep 15;92 (6):1541-9 [11745233.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):52-9 [15309332.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Jun;38(6):342-7; discussion 347-8 [9689817.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):860-6 [17011458.001]
  • [Cites] Ann Nucl Med. 2002 May;16(3):207-11 [12126046.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jun;32(6):653-9 [15711980.001]
  • [Cites] Int J Rad Appl Instrum A. 1988;39(4):311-4 [2838437.001]
  • [Cites] J Nucl Med. 2003 Dec;44(12 ):2027-32 [14660729.001]
  • [Cites] Clin Nucl Med. 2006 Dec;31(12 ):774-80 [17117071.001]
  • [Cites] J Nucl Med. 1995 Dec;36(12 ):2175-9 [8523100.001]
  • [Cites] Nucl Med Biol. 2002 Apr;29(3):281-7 [11929696.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):498-507 [16235683.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]
  • [Cites] J Nucl Med. 2006 Oct;47(10 ):1612-21 [17015896.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23 (18):4127-36 [15961760.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Dec;31(12 ):1659-72 [15565331.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 May;33(5):516-24 [16450140.001]
  • [Cites] Neurology. 1998 May;50(5):1316-22 [9595980.001]
  • [Cites] Neurosurg Rev. 1999 Dec;22(4):210-4 [10682929.001]
  • [Cites] J Nucl Med. 2005 Dec;46(12 ):1948-58 [16330557.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):746-50 [11702862.001]
  • [Cites] J Nucl Med. 2005 Jun;46(6):945-52 [15937304.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 May;29(5):632-40 [11976801.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2005 Jan;32(1):39-51 [15309329.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 Jun;30(6):868-73 [12692687.001]
  • [Cites] J Neurol Sci. 2006 Jul 15;246(1-2):85-94 [16603193.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):43-52 [10924970.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2004 Oct;75(10 ):1457-62 [15377696.001]
  • [Cites] J Nucl Med. 1998 May;39(5):778-85 [9591574.001]
  • [Cites] AJNR Am J Neuroradiol. 2006 Aug;27(7):1432-7 [16908552.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):276-87; discussion 287-8 [9007859.001]
  • [Cites] Ann Nucl Med. 2004 Jun;18(4):291-6 [15359921.001]
  • [Cites] Nat Med. 1998 Nov;4(11):1334-6 [9809561.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4714-21 [17947718.001]
  • (PMID = 18542957.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Dideoxynucleosides; AE28F7PNPL / Methionine; PG53R0DWDQ / alovudine
  •  go-up   go-down


74. Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, Aldape K, Prados MD: Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. Neuro Oncol; 2006 Jan;8(1):12-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area.
  • Additional statistically significant variables were as follows: among 517 glioblastoma patients, radiation treatment and being married; among 105 AA patients, inclusion of chemotherapy in the initial treatment; and among 106 patients with nonanaplastic oligodendroglial tumors, college education.

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pathol Oncol Res. 2000;6(1):46-52 [10749588.001]
  • [Cites] Can J Neurol Sci. 1998 Aug;25(3):197-201 [9706720.001]
  • [Cites] Pediatr Neurosurg. 2000 Jun;32(6):321-6 [10971194.001]
  • [Cites] Int J Oncol. 2000 Nov;17(5):963-9 [11029499.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] Clin Cancer Res. 1998 Oct;4(10):2447-54 [9796977.001]
  • [Cites] Clin Cancer Res. 1995 Dec;1(12):1617-22 [9815964.001]
  • [Cites] Clin Cancer Res. 1998 Dec;4(12):3031-5 [9865917.001]
  • [Cites] Eur J Cancer. 1998 Dec;34(14 Spec No):2241-7 [10070294.001]
  • [Cites] Cancer Res. 1999 Apr 15;59(8):1820-4 [10213484.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):203-11 [10363853.001]
  • [Cites] Neuroimaging Clin N Am. 1999 Nov;9(4):581-94 [10517935.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):675-80 [15542975.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):2040-4 [16103458.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):635-40 [11148662.001]
  • [Cites] Cancer Res. 2001 Feb 1;61(3):1122-8 [11221842.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • [Cites] Int J Cancer. 2002 Apr 1;98(4):609-15 [11920623.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1299-308 [12973855.001]
  • [Cites] Patient Educ Couns. 1999 Jul;37(3):215-30 [14528548.001]
  • [Cites] Cancer Res. 2004 Feb 15;64(4):1220-3 [14973082.001]
  • [Cites] CA Cancer J Clin. 2004 Mar-Apr;54(2):78-93 [15061598.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2618-25 [15102663.001]
  • [Cites] J Clin Oncol. 2004 Jul 1;22(13):2567-75 [15226324.001]
  • [Cites] Neuro Oncol. 2004 Jul;6(3):227-35 [15279715.001]
  • [Cites] Eur J Epidemiol. 2004;19(6):533-40 [15330125.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6503-10 [15374961.001]
  • [Cites] Eur J Cancer Prev. 2004 Oct;13(5):397-401 [15452452.001]
  • [Cites] J Psychosom Res. 2004 Aug;57(2):123-31; discussion 133-5 [15465065.001]
  • [Cites] Lancet. 1989 Oct 14;2(8668):888-91 [2571815.001]
  • [Cites] J Natl Cancer Inst. 1993 May 5;85(9):704-10 [8478956.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):255-68 [8293185.001]
  • [Cites] J Neurooncol. 1994;18(1):69-81 [8057137.001]
  • [Cites] Cancer Causes Control. 1995 May;6(3):240-56 [7612804.001]
  • [Cites] Epidemiol Rev. 1995;17(2):382-414 [8654518.001]
  • [Cites] Neurol Clin. 1996 May;14(2):273-90 [8827171.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):796-803 [9024718.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] Am J Epidemiol. 1997 Apr 1;145(7):581-93 [9098174.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1673-7 [9135006.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):1-10 [9420066.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] Cancer. 2000 May 15;88(10):2342-9 [10820357.001]
  • (PMID = 16443944.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES06717; United States / NIEHS NIH HHS / ES / R01 ES006717; United States / NCI NIH HHS / CA / R01 CA089032; United States / NCI NIH HHS / CA / CA89032; United States / NIEHS NIH HHS / ES / ES04705; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NCI NIH HHS / CA / CA52689; United States / NCI NIH HHS / CA / P50 CA097257; United States / NCI NIH HHS / CA / CA097257; United States / NCI NIH HHS / CA / R01 CA052689
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1871921
  •  go-up   go-down


75. Lima-Ramos V, Pacheco-Figueiredo L, Costa S, Pardal F, Silva A, Amorim J, Lopes JM, Reis RM: TP53 codon 72 polymorphism in susceptibility, overall survival, and adjuvant therapy response of gliomas. Cancer Genet Cytogenet; 2008 Jan 1;180(1):14-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • TP53 is a key tumor suppressor gene that encodes a transcriptional factor involved in several cellular mechanisms, including growth arrest, DNA repair, and induction of apoptosis.
  • No statistically significant differences were observed in the genotypic and allelic frequencies between glioma and control groups, and no statistically significant differences were observed with stratification of gliomas into distinct histological subtypes: astrocytic (n = 115), glioblastoma (n = 75), and oligodendroglial (n = 54) tumors.
  • In this first assessment of the role of TP53 Arg72Pro polymorphism in a large series of Portuguese glioma tumors, no association was observed with glioma susceptibility or overall survival, except for patients submitted to adjuvant therapy.
  • [MeSH-major] Brain Neoplasms / genetics. Genes, p53. Genetic Predisposition to Disease. Glioma / genetics. Polymorphism, Genetic
  • [MeSH-minor] Adult. Arginine. Case-Control Studies. Codon. Combined Modality Therapy. Female. Gene Frequency. Humans. Male. Middle Aged. Proline. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18068527.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline
  •  go-up   go-down


76. Maiuri F, Del Basso De Caro M, Siciliano A, Peca C, Vergara P, Mariniello G, Pettinato G: Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival. Clin Neuropathol; 2010 Mar-Apr;29(2):109-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of growth factors in brain tumors: correlation with tumor grade, recurrence and survival.
  • OBJECTIVE: The aim of this study is to evaluate the correlation between the expression of some growth factors (GFs) and the tumor grade, recurrence and survival of brain glial and ependymal tumors.
  • MATERIAL AND METHODS: The expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), tenascine, transforming growth factor (TGFbeta), isomeres, platelet-derived growth factor (PDGF) and p53 was studied in 40 primary brain tumors, both low-grade and high-grade, including astrocytomas, oligodendrogliomas, glioblastomas and ependymomas.
  • The same GFs were also studied in 46 specimens of recurrent tumors from the same patients.
  • The positivity and intensity of the immunohistochemical expression were correlated with the tumor grade, the interval and type of recurrence, and the survival.
  • RESULTS: The expression of all GFs, excepting TGFbeta1, TGFbetaRI and tenascine, was found to be correlated with the tumor grade in all tumors of both astroglial and oligodendroglial origin, whereas ependymomas showed significant differences only for EGFR.
  • Low-grade (Grade II) tumors recurring as anaplastic (Grade III) forms showed GF expression rather similar to initially high-grade gliomas and significantly higher than that of low-grade (Grade II) tumors in both initial surgery and recurrence.
  • Besides, low-grade (Grade II) tumors recurring as low-grade showed significantly longer median recurrence time (5.4 vs. 3.5 years) and better median survival (8.3 vs. 5.4 years) than those recurring as anaplastic forms (WHO III).
  • CONCLUSION: The immunohistochemical study of expression of VEGF, EGFR, TGFbeta2, TGFbeta3, PDGF and p53 in all low-grade (Grade II) brain gliomas at the first operation may help to differentiate cases with slower evolution and longer survival from those with higher potential of anaplastic transformation.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / metabolism. Brain Neoplasms / mortality. Brain Neoplasms / pathology. Intercellular Signaling Peptides and Proteins / biosynthesis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Neoplasm Recurrence, Local / metabolism. Prognosis. Young Adult


77. van den Bent MJ, Carpentier AF, Brandes AA, Sanson M, Taphoorn MJ, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Haaxma-Reiche H, Kros JM, van Kouwenhoven MC, Vecht CJ, Allgeier A, Lacombe D, Gorlia T: Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol; 2006 Jun 20;24(18):2715-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the RT arm, 82% of patients with tumor progression received chemotherapy.
  • Combined loss of 1p/19q identifies a favorable subgroup of oligodendroglial tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Oligodendroglioma / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Dose Fractionation. Female. Humans. Lomustine / therapeutic use. Loss of Heterozygosity. Male. Middle Aged. Procarbazine / therapeutic use. Survival Analysis. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. LOMUSTINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Oncol. 2007 Feb;4(2):78-9 [17228307.001]
  • [CommentIn] J Clin Oncol. 2006 Jun 20;24(18):2689-90 [16782906.001]
  • [CommentIn] Curr Neurol Neurosci Rep. 2007 May;7(3):189-90 [17488583.001]
  • [CommentIn] Nat Clin Pract Neurol. 2007 Jan;3(1):14-5 [17205067.001]
  • (PMID = 16782911.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 5J49Q6B70F / Vincristine; 7BRF0Z81KG / Lomustine; PCV protocol
  •  go-up   go-down


78. Rodriguez FJ, Scheithauer BW, Jenkins R, Burger PC, Rudzinskiy P, Vlodavsky E, Schooley A, Landolfi J: Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study. Am J Surg Pathol; 2007 Mar;31(3):351-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gliosarcoma arising in oligodendroglial tumors ("oligosarcoma"): a clinicopathologic study.
  • Gliosarcomas are morphologically biphasic tumors composed of glial and sarcomatous elements.
  • Only rare examples of gliosarcoma with oligodendroglial components have been reported.
  • Seven patients with oligodendroglial tumors and a sarcomatous component were identified.
  • At first resection, the tumors included grade II oligodendroglioma (n=3), grade III oligodendroglioma (n=1), grade II oligoastrocytoma (n=1), and grade III oligoastrocytoma (n=2).
  • The sarcomatous component developed in recurrent/progressive tumors in 6 cases but was a focal finding at first tumor resection in 1 and included fibrosarcoma (n=5), leiomyosarcoma (n=1), or pleomorphic myogenic sarcoma (n=1).
  • Rhabdoid change was a focal finding in the sarcomatous component of 1 tumor.
  • Gliosarcomas with oligodendroglial elements are rare.
  • [MeSH-major] Brain Neoplasms / pathology. Gliosarcoma / pathology. Neoplasms, Second Primary / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Brain / surgery. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Combined Modality Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging

  • Genetic Alliance. consumer health - Gliosarcoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325476.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


79. Majumdar K, Radotra BD, Vasishta RK, Pathak A: Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas. Surg Neurol; 2009 Jul;72(1):54-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor expression correlates with tumor grade and proliferative activity in human oligodendrogliomas.
  • BACKGROUND: For the last one and a half decade, it has been found that platelet-derived growth factor (PDGF) promotes glial tumor growth through autocrine and paracrine loops, by expression of PDGFalpha receptor (PDGFRalpha) on glioma cells and PDGFbeta receptor (PDGFRbeta) on proliferating endothelial cells.
  • However, studies on oligodendrogliomas, correlating expression of PDGF and its receptor with tumor grade and proliferative activity, through MIB-1 labeling index (LI) are relatively few as compared to astroglial counterpart.
  • METHODS: Formalin-fixed paraffin-embedded tissues from 55 cases of oligodendrogliomas (34 World Health Organization [WHO] grade II and 21 WHO grade III tumors) were subjected to immunohistochemistry.
  • The PDGF expression scores had a positive correlation with MIB-1 LI, irrespective of tumor grade (Pearson's correlation coefficient, r = 0.566; P < .001).
  • However, there was no significant difference of PDGFRalpha expression between 2 grades of tumors.
  • CONCLUSIONS: The results of this study showed that MIB-1 LI is a rapid and cost-effective modality for predicting tumor grade in oligodendrogliomas.
  • Immunohistochemistry for PDGF was found to be useful in differentiating various grades of oligodendroglioma, and therefore, it may be involved in tumor cell proliferation and malignant transformation.
  • Platelet-derived growth factor receptor alpha, although expressed in oligodendroglial neoplasms, was not found to be useful in predicting tumor grade.
  • [MeSH-major] Antibodies, Antinuclear / metabolism. Antibodies, Monoclonal / metabolism. Biomarkers, Tumor / metabolism. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Platelet-Derived Growth Factor / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Proliferation. Child. Cost-Benefit Analysis. Diagnosis, Differential. Female. Humans. Immunohistochemistry / economics. Immunohistochemistry / methods. Male. Middle Aged. Predictive Value of Tests. Retrospective Studies. Sensitivity and Specificity. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19559929.001).
  • [ISSN] 1879-3339
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / MIB-1 antibody; 0 / Platelet-Derived Growth Factor
  •  go-up   go-down


80. Hirose T, Ishizawa K, Shimada S: Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors. Neuropathology; 2010 Dec;30(6):586-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of in situ demonstration of 1p loss and p53 overexpression in pathologic diagnosis of oligodendroglial tumors.
  • To improve the diagnostic accuracy of oligodendroglial tumors and to find more convenient parameters that could predict the cytogenetic status, oligodendroglial and astrocytic tumors were cytogenetically and immunohistochemically investigated.
  • Materials included 22 oligodendroglial tumors (15 oligodendrogliomas and 7 oligoastrocytomas) and 20 astrocytic tumors.
  • Furthermore, TP53 mutation analyses were carried out on three oligodendroglial tumors showing p53 protein overexpression with a direct sequence analysis.
  • Our FISH studies demonstrated 1p loss in 73% of oligodendroglial tumors (80% oligodendrogliomas and 57% oligoastrocytomas) and in only 10% of astrocytic tumors.
  • There were no clear-cut morphologic differences between 1p-deleted and 1p-intact oligodendroglial tumors.
  • GFAP and Olig2 were expressed in most oligodendroglial and astrocytic tumors, and their cellular localization was almost independent of each other.
  • Overexpression of p53 was observed in five oligodendroglial tumors, all of which were 1p-intact.
  • In comparison, 16 oligodendroglial tumors with 1p deletion showed no overexpression of p53.
  • TP53 missense mutations were detected in three of the p53 overexpressed oligodendroglial tumors studied.
  • Our results suggest that 1p loss is almost specific to oligodendroglial tumors.
  • Although the prediction of 1p status based solely on the morphologic features seems to be difficult, the immunohistochemistry for p53 is a useful tool in that p53 overexpression is closely related to the 1p-intact status in oligodendroglial tumors.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Chromosomes, Human, Pair 1 / genetics. Oligodendroglioma / diagnosis. Tumor Suppressor Protein p53 / biosynthesis
  • [MeSH-minor] Adult. Aged. Basic Helix-Loop-Helix Transcription Factors / biosynthesis. Female. Gene Deletion. Glial Fibrillary Acidic Protein / biosynthesis. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Male. Middle Aged. Mutation. Nerve Tissue Proteins / biosynthesis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Japanese Society of Neuropathology.
  • (PMID = 20408960.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Transcription Factors; 0 / Glial Fibrillary Acidic Protein; 0 / Nerve Tissue Proteins; 0 / OLIG2 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


81. Walker C, du Plessis DG, Joyce KA, Fildes D, Gee A, Haylock B, Husband D, Smith T, Broome J, Warnke PC: Molecular pathology and clinical characteristics of oligodendroglial neoplasms. Ann Neurol; 2005 Jun;57(6):855-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathology and clinical characteristics of oligodendroglial neoplasms.
  • To evaluate the role of molecular genetics in the routine clinic, we investigated allelic imbalance at 1p36, 19q13, 17p13, 10p12-15, and 10q22-26 and p53 mutation in 100 oligodendroglial neoplasms diagnosed at a single treatment center between 2000 and 2003.
  • Genotype was unrelated to tumor location and could not distinguish high-grade tumors that presented de novo from those that progressed from a previous lower grade malignancy.
  • In this recently diagnosed unselected series, clinical differences in tumors with and without the -1p/-19q genotype support a genetic approach to aid diagnosis and prognostication for oligodendroglial neoplasms.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Oligodendroglioma / genetics. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Aged. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 10. Chromosomes, Human, Pair 17. Chromosomes, Human, Pair 19. Female. Genetic Testing. Genotype. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / pathology. Phenotype. Prognosis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15929038.001).
  • [ISSN] 0364-5134
  • [Journal-full-title] Annals of neurology
  • [ISO-abbreviation] Ann. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


82. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A: Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol; 2008 Dec;116(6):597-602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the IDH1 codon 132 mutation in brain tumors.
  • We analyzed the genomic region spanning wild type R132 of IDH1 by direct sequencing in 685 brain tumors including 41 pilocytic astrocytomas, 12 subependymal giant cell astrocytomas, 7 pleomorphic xanthoastrocytomas, 93 diffuse astrocytomas, 120 adult glioblastomas, 14 pediatric glioblastomas, 105 oligodendrogliomas, 83 oligoastrocytomas, 31 ependymomas, 58 medulloblastomas, 9 supratentorial primitive neuroectodermal tumors, 17 schwannomas, 72 meningiomas and 23 pituitary adenomas.
  • The very high frequency of IDH1 mutations in WHO grade II astrocytic and oligodendroglial gliomas suggests a role in early tumor development.
  • [MeSH-major] Brain Neoplasms / genetics. Isocitrate Dehydrogenase / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18985363.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  •  go-up   go-down


83. Stockhammer F, von Deimling A, Synowitz M, Blechschmidt C, van Landeghem FK: Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II. J Mol Histol; 2008 Oct;39(5):553-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of glucose transporter 1 is associated with loss of heterozygosity of chromosome 1p in oligodendroglial tumors WHO grade II.
  • Objective Oligodendroglial tumors with a loss of heterozygosity of 1p (LOH1p) appear to have a better prognosis than oligodendrogliomas without LOH.
  • Previously, we reported glucose uptake in low-grade oligodendroglial tumors to be related to LOH 1p status.
  • Results Confocal microscopy depicted immunoreaction for GLUT-1, -3 and -12 in the cytoplasm of the tumor cells.
  • GLUT-1 expression in tumors with LOH 1p was significantly lower than in tumors with wild type 1p status (P = 0.0017).
  • Conclusion Expression of GLUT-1 is significantly reduced in low-grade oligodendroglial tumors harboring LOH 1p.
  • [MeSH-major] Brain Neoplasms / metabolism. Chromosomes, Human, Pair 1 / metabolism. Glioma / metabolism. Glucose Transporter Type 1 / biosynthesis. Loss of Heterozygosity
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Neoplastic / genetics. Glucose Transport Proteins, Facilitative / biosynthesis. Glucose Transport Proteins, Facilitative / genetics. Glucose Transporter Type 3 / biosynthesis. Glucose Transporter Type 3 / genetics. Humans. Male. Microscopy, Confocal / methods. Middle Aged. Tumor Suppressor Protein p53 / biosynthesis. Tumor Suppressor Protein p53 / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Feb 1;65(3):999-1006 [15705901.001]
  • [Cites] J Neurosurg. 2007 Apr;106(4):633-7 [17432715.001]
  • [Cites] J Pathol. 2001 Sep;195(1):72-9 [11568893.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):2035-42 [12673735.001]
  • [Cites] Acta Neuropathol. 2007 Feb;113(2):119-27 [17160531.001]
  • [Cites] Cancer Res. 1992 Jul 15;52(14):3972-9 [1617673.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):225-33 [12706881.001]
  • [Cites] Cancer Res. 2004 Apr 1;64(7):2627-33 [15059920.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2002 Mar;282(3):E733-8 [11832379.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Jan 15;89(2):733-7 [1731347.001]
  • [Cites] Cancer Chemother Pharmacol. 2007 Mar;59(4):495-505 [16906425.001]
  • [Cites] J Biol Chem. 1990 Oct 15;265(29):18035-40 [2211679.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neurochem. 1993 Dec;61(6):2048-53 [8245960.001]
  • [Cites] J Nucl Med. 2006 Mar;47(3):410-8 [16513609.001]
  • [Cites] Br J Cancer. 1997;75(2):161-8 [9010020.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1986;409(2):127-47 [2424168.001]
  • [Cites] J Neurochem. 2006 Nov;99(4):1049-61 [16899068.001]
  • [Cites] Neuro Oncol. 2002 Jul;4(3):171-8 [12084347.001]
  • [Cites] Brain Res Mol Brain Res. 1994 Nov;27(1):51-7 [7877454.001]
  • [Cites] Acta Neuropathol. 2002 Mar;103(3):267-75 [11907807.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 Jan;64(1):10-4 [15715080.001]
  • [Cites] Am J Pathol. 1986 Dec;125(3):443-9 [3541638.001]
  • [Cites] J Neurosurg. 2006 Apr;104(4):542-50 [16619658.001]
  • [Cites] Nat Med. 1998 Jul;4(7):844-7 [9662379.001]
  • [Cites] Diabetes Care. 1990 Mar;13(3):198-208 [2407475.001]
  • [Cites] Cancer Lett. 2007 Nov 18;257(2):244-51 [17910902.001]
  • [Cites] Cancer. 2001 Sep 1;92(5):1144-50 [11571727.001]
  • [Cites] Glia. 1995 May;14(1):43-54 [7615345.001]
  • [Cites] Placenta. 2005 Jan;26(1):67-72 [15664413.001]
  • [Cites] Adv Anat Pathol. 2001 Jan;8(1):14-20 [11152090.001]
  • [Cites] Diabetes. 1987 Apr;36(4):546-9 [3028891.001]
  • [Cites] Ann Neurol. 1990 Dec;28(6):758-65 [2178329.001]
  • [Cites] Brain Res. 1998 Jun 22;797(1):65-72 [9630522.001]
  • [Cites] J Neurooncol. 2003 Sep;64(3):227-37 [14558598.001]
  • [Cites] Placenta. 2003 May;24(5):566-70 [12744934.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Jan 31;182(2):703-11 [1734877.001]
  • [Cites] Neuropathol Appl Neurobiol. 2000 Feb;26(1):91-7 [10736070.001]
  • [Cites] J Clin Invest. 1987 Feb;79(2):657-61 [3027132.001]
  • [Cites] Histochem J. 1989 Jan;21(1):47-51 [2663794.001]
  • [Cites] Ann Neurol. 1988 Dec;24(6):757-64 [3207358.001]
  • (PMID = 18726700.001).
  • [ISSN] 1567-2379
  • [Journal-full-title] Journal of molecular histology
  • [ISO-abbreviation] J. Mol. Histol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Glucose Transport Proteins, Facilitative; 0 / Glucose Transporter Type 1; 0 / Glucose Transporter Type 3; 0 / SLC2A1 protein, human; 0 / SLC2A12 protein, human; 0 / SLC2A3 protein, human; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


84. Kordes U, Hagel C: Expression of SOX9 and SOX10 in central neuroepithelial tumor. J Neurooncol; 2006 Nov;80(2):151-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of SOX9 and SOX10 in central neuroepithelial tumor.
  • We have examined the pattern of expression for SOX9 and SOX10 in primary brain tumors by immunohistochemistry.
  • Pediatric and adult high grade tumors display strong nuclear staining for both SOX9 and SOX10 (astrocytic, oligodendroglial and primitive neuroectodermal tumors).
  • [MeSH-minor] Adolescent. Adult. Astrocytes / metabolism. Cell Nucleus / pathology. Child. Child, Preschool. Gene Expression Regulation, Neoplastic / genetics. Gliosis / pathology. Humans. Immunohistochemistry. Oligodendroglia / metabolism. Paraffin Embedding. SOX9 Transcription Factor. SOXE Transcription Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Biol. 2005 May 15;281(2):309-17 [15893981.001]
  • [Cites] Oncogene. 2005 Jun 2;24(24):3896-905 [15750623.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):115-27 [16205963.001]
  • [Cites] Genes Dev. 2003 Jul 1;17(13):1677-89 [12842915.001]
  • [Cites] Neoplasia. 2005 Jun;7(6):575-84 [16036108.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):15178-83 [14645703.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 15;27(6):1409-20 [10037800.001]
  • [Cites] Ann Neurol. 1996 Apr;39(4):481-9 [8619526.001]
  • [Cites] Genes Dev. 2002 Jan 15;16(2):165-70 [11799060.001]
  • [Cites] Glia. 2001 Jun;34(4):283-95 [11360301.001]
  • [Cites] Brain Res Mol Brain Res. 2001 Aug 15;92(1-2):193-200 [11483257.001]
  • [Cites] Dev Biol. 2005 Jan 1;277(1):155-69 [15572147.001]
  • [Cites] Curr Opin Neurobiol. 2002 Feb;12(1):26-34 [11861161.001]
  • [Cites] Brain Res Dev Brain Res. 2005 Jun 30;157(2):209-13 [15878625.001]
  • [Cites] Oncogene. 2003 Apr 17;22(15):2361-73 [12700671.001]
  • [Cites] Nature. 2002 Jan 24;415(6870):436-42 [11807556.001]
  • [Cites] Curr Opin Neurobiol. 2002 Jun;12(3):244-9 [12049929.001]
  • (PMID = 16791471.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / High Mobility Group Proteins; 0 / SOX10 protein, human; 0 / SOX9 Transcription Factor; 0 / SOX9 protein, human; 0 / SOXE Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


85. Muller PJ, Wilson BC: Photodynamic therapy of brain tumors--a work in progress. Lasers Surg Med; 2006 Jun;38(5):384-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of brain tumors--a work in progress.
  • BACKGROUND AND OBJECTIVES: PDT has been used in the treatment of malignant brain tumors.
  • STUDY DESIGN AND METHODS: We examined the records of 112 patients with malignant gliomas, metastatic brain tumors and meningiomas treated with Photofrin-PDT at St. Michael's Hospital, Toronto.
  • The greater the degree of oligodendroglial involvement the longer was the survival.
  • [MeSH-major] Brain Neoplasms / drug therapy. Dihematoporphyrin Ether / therapeutic use. Photochemotherapy. Photosensitizing Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma / drug therapy. Carcinoma / mortality. Carcinoma / secondary. Female. Glioma / drug therapy. Glioma / mortality. Humans. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / mortality. Meningioma / drug therapy. Meningioma / mortality. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 Wiley-Liss, Inc.
  • (PMID = 16788926.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA43892
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 97067-70-4 / Dihematoporphyrin Ether
  •  go-up   go-down


86. Soffietti R, Baumert BG, Bello L, von Deimling A, Duffau H, Frénay M, Grisold W, Grant R, Graus F, Hoang-Xuan K, Klein M, Melin B, Rees J, Siegal T, Smits A, Stupp R, Wick W, European Federation of Neurological Societies: Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task Force. Eur J Neurol; 2010 Sep;17(9):1124-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Diffuse infiltrative low-grade gliomas of the cerebral hemispheres in the adult are a group of tumors with distinct clinical, histological and molecular characteristics, and there are still controversies in management.
  • Younger age, normal neurological examination, oligodendroglial histology and 1p loss are favorable prognostic factors.
  • Neurocognitive deficits are frequent and can be caused by the tumor itself, tumor-related epilepsy, treatments and psychological distress.

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20718851.001).
  • [ISSN] 1468-1331
  • [Journal-full-title] European journal of neurology
  • [ISO-abbreviation] Eur. J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] England
  •  go-up   go-down


87. Zhang SK, Lu DH, Piao YS, Cai YN, Xu QZ: [Study of loss of heterozygosity in oligodendroglial tumors by real-time quantitative polymerase chain reaction-based microsatellite analysis]. Zhonghua Bing Li Xue Za Zhi; 2006 Dec;35(12):731-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study of loss of heterozygosity in oligodendroglial tumors by real-time quantitative polymerase chain reaction-based microsatellite analysis].
  • OBJECTIVE: To study the loss of heterozygosity (LOH) at chromosomes 1p or 19q in oligodendroglial tumors.
  • METHODS: Twenty-eight cases of oligodendroglial tumors were enrolled into the study.
  • Real-time quantitative polymerase chain reaction-based microsatellite analysis was performed on paraffin-embedded tumor tissues in order to study the status of chromosomes 1p and 19q.
  • RESULTS: Among the 28 cases of oligodendroglial tumors, 24 cases (85.7%) showed 1p LOH, while 18 cases (64.3%) showed 19q LOH and 17 cases (60.7%) showed LOH of both 1p and 19q.
  • CONCLUSIONS: Real-time quantitative polymerase chain reaction-based microsatellite analysis is a rapid and specific way in detecting LOH in paraffin-embedded tumor tissues.
  • LOH at 1p or 19q is present in majority of the oligodendroglial tumors studied.
  • [MeSH-major] Brain Neoplasms / genetics. Loss of Heterozygosity. Microsatellite Repeats. Oligodendroglioma / genetics. Polymerase Chain Reaction / methods
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374257.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


88. Nielsen MS, Christensen HC, Kosteljanetz M, Johansen C: Incidence of and survival from oligodendroglioma in Denmark, 1943-2002. Neuro Oncol; 2009 Jun;11(3):311-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We established the nationwide, population-based incidence of oligodendroglioma in Denmark during 59 years of monitoring and compared the overall survival of patients with oligodendroglial tumors during the periods 1943-1977 and 1978-2002.
  • [MeSH-major] Brain Neoplasms / epidemiology. Oligodendroglioma / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age Distribution. Child. Child, Preschool. Denmark / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Kaplan-Meier Estimate. Male. Registries. Young Adult

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):479-90 [14585228.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):675-80 [15542975.001]
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] J Clin Oncol. 2004 Aug 1;22(15):3133-8 [15284265.001]
  • [Cites] Ann Neurol. 1988 Apr;23(4):360-4 [3382171.001]
  • [Cites] Int J Epidemiol. 1988 Mar;17(1):44-9 [3384548.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Nov 1;45(4):923-9 [10571199.001]
  • [Cites] Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 [10598694.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Mar;60(3):248-62 [11245209.001]
  • [Cites] Semin Oncol. 2001 Aug;28(4 Suppl 13):13-8 [11550134.001]
  • [Cites] Neuro Oncol. 1999 Jan;1(1):61-8 [11550303.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):316-24 [11872276.001]
  • [Cites] Surg Neurol. 2002 Aug;58(2):111-7; discussion 117 [12453646.001]
  • [Cites] Neurol India. 2002 Dec;50(4):462-6 [12577096.001]
  • [Cites] J Neuropathol Exp Neurol. 2003 Feb;62(2):111-26 [12578221.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):296-303 [12694851.001]
  • [Cites] Cancer. 2003 May 1;97(9):2254-61 [12712480.001]
  • [Cites] Am J Clin Oncol. 2003 Jun;26(3):e60-6 [12796617.001]
  • [Cites] J Clin Oncol. 2003 Jul 1;21(13):2525-8 [12829671.001]
  • [Cites] Acta Oncol. 2003;42(3):179-85 [12852693.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] APMIS. 1989 Jun;97(6):547-55 [2736107.001]
  • [Cites] IARC Sci Publ. 1991;(95):126-58 [1894318.001]
  • [Cites] IARC Sci Publ. 1991;(95):220-36 [1894325.001]
  • [Cites] J Neurosurg. 1992 Mar;76(3):428-34 [1738022.001]
  • [Cites] Neuroepidemiology. 1993;12(5):270-9 [8309502.001]
  • [Cites] Acta Neurol Scand. 1994 Nov;90(5):312-7 [7887130.001]
  • [Cites] J Neurosurg. 1995 Dec;83(6):999-1003 [7490645.001]
  • [Cites] Neurol Clin. 1995 Nov;13(4):861-73 [8584001.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Oct 1;36(3):549-56 [8948338.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 15;37(2):399-403 [9069313.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1195-202 [9070498.001]
  • [Cites] Cancer. 1997 Apr 1;79(7):1381-93 [9083161.001]
  • [Cites] J Neurooncol. 1997 Aug;34(1):37-59 [9210052.001]
  • [Cites] Dan Med Bull. 1997 Nov;44(5):535-9 [9408738.001]
  • [Cites] Acta Neuropathol. 1998 May;95(5):493-504 [9600596.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):434-6 [10199331.001]
  • [Cites] J Neurosurg. 2003 Nov;99(5):854-62 [14609165.001]
  • (PMID = 19066344.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2718975
  •  go-up   go-down


89. Merrell R, Nabors LB, Perry A, Palmer CA: 1p/19q chromosome deletions in metastatic oligodendroglioma. J Neurooncol; 2006 Nov;80(2):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extracranial metastasis of primary brain tumors is a rare phenomenon.
  • Although the bone metastasis was non-informative, the primary intracranial tumor revealed codeletions of the 1p and 19q chromosomal arms, commonly recognized as the genetically favorable profile of oligodendrogliomas.
  • Along with the reported literature, our data suggest that despite their generally favorable behavioral profiles, oligodendroglial tumors with 1p/19q deletions may be more prone to metastasis as they progress.
  • [MeSH-major] Bone Marrow Neoplasms / genetics. Bone Marrow Neoplasms / secondary. Bone Neoplasms / genetics. Bone Neoplasms / secondary. Brain Neoplasms / pathology. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Oligodendroglioma / genetics. Oligodendroglioma / secondary. Spinal Neoplasms / genetics. Spinal Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Fatal Outcome. Female. Humans. In Situ Hybridization. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Hum Pathol. 1979 Jul;10(4):453-67 [381159.001]
  • [Cites] Acta Cytol. 2003 May-Jun;47(3):467-9 [12789933.001]
  • [Cites] Neurology. 1989 Dec;39(12):1593-6 [2685656.001]
  • [Cites] Can J Neurol Sci. 2004 Feb;31(1):102-8 [15038479.001]
  • [Cites] Neuro Oncol. 2001 Jul;3(3):141-51 [11465394.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):839-45 [11309331.001]
  • [Cites] Surg Neurol. 2003 Nov;60(5):443-56 [14572971.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):314-22 [15099021.001]
  • [Cites] Can J Neurol Sci. 2001 Aug;28(3):215-23 [11513339.001]
  • [Cites] Front Biosci. 2003 Jan 01;8:a1-9 [12456321.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Dec;23(6):516-20 [9460719.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):265-71 [15015656.001]
  • [Cites] Clin Neurol Neurosurg. 2002 Sep;104(4):383-6 [12140111.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):267-73 [12675321.001]
  • (PMID = 16710746.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Weller M: [Chemotherapy for brain tumors in adult patients]. Nervenarzt; 2008 Feb;79(2):231-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Chemotherapy for brain tumors in adult patients].
  • Chemotherapy has become a third major treatment option for patients with brain tumors, in addition to surgery and radiotherapy.
  • Outside such clinical trials chemotherapy is used in addition to radiotherapy, e.g., in anaplastic astrocytoma, medulloblastoma or germ cell tumors, or as an alternative to radiotherapy, e.g., in anaplastic oligodendroglial tumors or low-grade gliomas.
  • In contrast, there is no established role for chemotherapy in other tumors such as ependymomas, meningiomas or neurinomas.
  • Primary cerebral lymphomas are probably the only brain tumors which can be cured by chemotherapy alone and only by chemotherapy.
  • The chemotherapy of brain metastases follows the recommendations for the respective primary tumors.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / drug therapy. Glioma / drug therapy. Lymphoma / drug therapy
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Combined Modality Therapy. DNA Methylation. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Dacarbazine / adverse effects. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Genetic Markers / genetics. Humans. Prognosis. Promoter Regions, Genetic / genetics. Topotecan / adverse effects. Topotecan / therapeutic use. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2005 Feb;71(3):271-6 [15735916.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):44-55; discussion 55-6 [12182434.001]
  • [Cites] Neurologist. 2006 Jul;12(4):179-87 [16832237.001]
  • [Cites] Curr Treat Options Neurol. 2006 Jul;8(4):346-57 [16942677.001]
  • [Cites] Nervenarzt. 2003 Dec;74(12):1139-49 [14994756.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] J Neurol. 2005 Mar;252(3):291-9 [16189725.001]
  • [Cites] Cancer. 2005 Jul 1;104(1):143-8 [15912507.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3357-61 [17664483.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2707-14 [16782910.001]
  • [Cites] Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 [16482400.001]
  • [Cites] Clin Cancer Res. 2007 Feb 15;13(4):1253-9 [17317837.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2715-22 [16782911.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Dec;20(6):1287-95 [17113463.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • (PMID = 18253773.001).
  • [ISSN] 0028-2804
  • [Journal-full-title] Der Nervenarzt
  • [ISO-abbreviation] Nervenarzt
  • [Language] ger
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers; 0 / Tumor Suppressor Proteins; 7GR28W0FJI / Dacarbazine; 7M7YKX2N15 / Topotecan; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes; YF1K15M17Y / temozolomide
  •  go-up   go-down


91. Kim SH, Kim H, Kim TS: Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors. Acta Neuropathol; 2005 Jul;110(1):27-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical, histological, and immunohistochemical features predicting 1p/19q loss of heterozygosity in oligodendroglial tumors.
  • To identify a better diagnostic criteria for oligodendroglial tumors, we investigated the clinical, histological, and immunohistochemical features that would be able to predict a 1p/19q loss of heterozygosity (LOH) in these tumors.
  • We performed a PCR-based LOH test with the 1p and 19q microsatellite markers by microdissecting tumor in 56 samples (44 oligodendrogliomas and 12 mixed oligoastrocytomas) of paraffin-embedded tissue.
  • Patients with oligodendroglial tumors with 1p/19q LOH had a statistically significant better prognosis for overall survival.
  • Comparative analysis of several features indicated that the 1p/19q LOH tumors were associated with two histological features, "tumor cellularity" and "perinuclear halo," and low O(6)-methylguanine-DNA-methyltransferase (MGMT) expression and high cytoplasmic glutathione S-transferase pi (GST-pi) expression.
  • Using the new features, we could predict the 1p/19q status of oligodendroglial tumors with greater than 90% accuracy.
  • Therefore, applying these features in clinical practice, would be helpful in clarifying oligodendroglial tumor diagnosis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / genetics. Glioma / diagnosis. Glioma / genetics
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Chromosomes, Human, Pair 1. Chromosomes, Human, Pair 19. Female. Humans. Immunohistochemistry. Loss of Heterozygosity. Male. Middle Aged. Polymerase Chain Reaction. Sensitivity and Specificity. Survival Analysis


92. Mut M, Güler-Tezel G, Lopes MB, Bilginer B, Ziyal I, Ozcan OE: Challenging diagnosis: oligodendroglioma versus extraventricular neurocytoma. Clin Neuropathol; 2005 Sep-Oct;24(5):225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He presented with intratumoral hemorrhage and he underwent radical resection of tumor in 2003.
  • Histopathological examination of the recurrent tumor showed anaplastic progression with confusing immunohistochemical (IHC) results; the tumor was positive for NeuN and synaptophysin staining.
  • The question arisen was whether the recurrent tumor was an oligodendroglioma with neuronal differentiation or an extraventricular neurocytoma initially misdiagnosed as oligodendroglioma.
  • Current diagnostic methods of oligodendroglial tumors are discussed in context of differentiating oligodendrogliomas from other clear cell neoplasms of CNS, especially from extraventricular neurocytomas.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasm Recurrence, Local / pathology. Neurocytoma / pathology. Oligodendroglioma / pathology
  • [MeSH-minor] Adult. Chromosome Deletion. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 19 / genetics. Diagnosis, Differential. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Magnetic Resonance Imaging. Male. Nerve Tissue Proteins / biosynthesis. Synaptophysin / biosynthesis

  • Genetic Alliance. consumer health - Oligodendroglioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16167546.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Nerve Tissue Proteins; 0 / Synaptophysin
  •  go-up   go-down


93. Vordermark D, Ruprecht K, Rieckmann P, Roggendorf W, Vince GH, Warmuth-Metz M, Kölbl O, Flentje M: Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer; 2006;6:247
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26).
  • BACKGROUND: The presence of an oligodendroglial component within a glioblastoma multiforme (GBM) is considered a prognostically favorable factor, but the clinical outcome of patients with glioblastoma multiforme with oligodendroglial component (GBMO) after combined post-operative radiotherapy and chemotherapy has rarely been reported.
  • RESULTS: Neuropathological re-evaluation revealed GBM with an oligodendroglial component of 30% or less in five cases, predominant oligoastrocytic tumors with focal areas of GBM in four patients and WHO grade III oligoastrocytoma with questionable transition to GBM in one patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / pathology. Chemotherapy, Adjuvant. Glioblastoma / pathology. Oligodendroglioma / pathology. Radiotherapy, Adjuvant
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Craniotomy. Disease Progression. Disease-Free Survival. Female. Humans. Life Tables. Male. Middle Aged. Nimustine / administration & dosage. Oligodendroglia / pathology. Prognosis. Survival Analysis. Teniposide / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Glioblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMC Cancer. 2005;5:55 [15924621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):296-7; author reply 297 [15850943.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10):987-96 [15758009.001]
  • [Cites] Acta Neuropathol. 2001 Apr;101(4):311-20 [11355302.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Sep;60(9):863-71 [11556543.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Lancet. 2002 Mar 23;359(9311):1011-8 [11937180.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1602-7 [12670911.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3276-84 [12947063.001]
  • [Cites] Strahlenther Onkol. 2003 Sep;179(9):606-14 [14628126.001]
  • [Cites] J Neurooncol. 2003 Nov;65(2):127-34 [14686732.001]
  • [Cites] Histopathology. 2004 Jun;44(6):555-60 [15186270.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jan 1;40(1):51-5 [9422557.001]
  • [Cites] J Clin Oncol. 1994 Oct;12(10):2013-21 [7931469.001]
  • [Cites] Arq Neuropsiquiatr. 2004 Dec;62(4):1074-8 [15608972.001]
  • (PMID = 17049083.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0S726V972K / Nimustine; 957E6438QA / Teniposide
  • [Other-IDs] NLM/ PMC1621074
  •  go-up   go-down


94. Idbaih A, Boisselier B, Marie Y, El Hallani S, Sanson M, Crinière E, Rodero M, Carpentier C, Paris S, Laigle-Donadey F, Ducray F, Hoang-Xuan K, Delattre JY: TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet; 2007 Sep;177(2):103-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors.
  • Such results were also reported in brain tumors, notably in astrocytomas.
  • This SNP has never been precisely investigated in oligodendroglial tumors.
  • We retrospectively analyzed blood samples of 275 oligodendroglial tumor patients for the TP53 codon 72 polymorphism and compared them with a series of 144 healthy controls.
  • This suggests no association between oligodendroglial tumors and the SNP in codon 72 of TP53.
  • [MeSH-major] Brain Neoplasms / genetics. Chromosomes, Human, Pair 1 / genetics. Codon. Oligodendroglioma / genetics. Polymorphism, Genetic / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Aged. Astrocytoma / genetics. Astrocytoma / metabolism. Case-Control Studies. DNA, Neoplasm / blood. DNA, Neoplasm / genetics. DNA, Neoplasm / metabolism. Female. Genotype. Glioma / genetics. Glioma / metabolism. Humans. Immunoenzyme Techniques. Male. Microsatellite Repeats. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854663.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


95. Hiremath GK, Bingaman WE, Prayson RA, Nair D: Oligoastrocytoma presenting with intractable epilepsy. Epileptic Disord; 2007 Sep;9(3):315-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Oligoastrocytomas (OA) are mixed gliomas with distinct oligodendroglial and astrocytic neoplastic components.
  • Tumors arose from the left side in all patients and from the temporal lobe in five patients.
  • There were no surgical complications, clinical or radiographic tumor recurrence at a mean follow up period of 3.2 years (range 2-8).
  • CONCLUSION: As a result of our small sample size, general conclusions may be imprecise, but this review suggests that OA behave similar to other tumors related to intractable epilepsy: they usually have a preoperative seizure course of many years, an excellent rate of seizure-freedom following surgery, and are in general, low-grade tumors with an indolent course for which serial imaging is sufficient follow-up.
  • [MeSH-major] Astrocytoma / complications. Brain Neoplasms / complications. Epilepsy / drug therapy. Epilepsy / etiology
  • [MeSH-minor] Adolescent. Adult. Anticonvulsants / therapeutic use. Craniotomy. Drug Resistance. Epilepsy, Complex Partial / etiology. Epilepsy, Complex Partial / surgery. Female. Humans. Magnetic Resonance Imaging. Male. Memory / physiology. Neoplasm Recurrence, Local. Neurosurgical Procedures. Temporal Lobe / pathology. Temporal Lobe / surgery

  • Genetic Alliance. consumer health - Epilepsy.
  • Genetic Alliance. consumer health - Oligoastrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884756.001).
  • [ISSN] 1294-9361
  • [Journal-full-title] Epileptic disorders : international epilepsy journal with videotape
  • [ISO-abbreviation] Epileptic Disord
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


96. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol; 2009 Oct;118(4):469-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
  • IDH2 encoding mitochondrial NADP+-dependent isocitrate dehydrogenase is also mutated in these tumors, albeit at much lower frequencies.
  • Preliminary data suggest an importance of IDH1 mutation for prognosis showing that patients with anaplastic astrocytomas, oligodendrogliomas and oligoastrocytomas harboring IDH1 mutations seem to fare much better than patients without this mutation in their tumors.
  • We report on an inverse association of IDH1 and IDH2 mutations in these gliomas and a non-random distribution of the mutation types within the tumor entities.
  • IDH1 mutations of the R132C type are strongly associated with astrocytoma, while IDH2 mutations predominantly occur in oligodendroglial tumors.
  • [MeSH-major] Brain Neoplasms / genetics. Glioma / genetics. Isocitrate Dehydrogenase / genetics
  • [MeSH-minor] Adult. Age Factors. Brain / pathology. Cell Differentiation. DNA Mutational Analysis. Female. Humans. Male. Middle Aged. Mutation. Prognosis. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554337.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] EC 1.1.1.41 / Isocitrate Dehydrogenase
  •  go-up   go-down


97. Wu A, Aldape K, Lang FF: High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors. J Neurooncol; 2010 Aug;99(1):57-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors.
  • It has been reported recently that oligodendroglial tumors arising in the insula rarely harbor co-deletions of chromosomes 1p and 19q, a molecular signature which is associated with a good prognosis and increased responsiveness to radiation and chemotherapy compared with tumors in which 1p and/or 19q is intact.
  • In the context of this claim, we analyzed a series of insular oligodendroglial tumors in order to determine the frequency of 1p/19q co-deletion in tumors arising in this region.
  • Seven of the eight tumors with co-deletion of 1p/19q were WHO grade II gliomas.
  • There were no statistical differences between tumors with 1p/19q co-deletion compared to those with 1p and/or 19q intact in terms of age, preoperative KPS, presenting symptoms, left versus right lateralization, tumor location (purely insular versus extension into frontal or temporal lobe), preoperative tumor size.
  • In contradistinction to previous reports, loss of 1p/19q occurs commonly in insular oligodendroglial tumors.
  • With respect to 1p/19q, insular gliomas do not appear to be distinct from gliomas arising elsewhere in the brain.